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CHAPTER I 
DIABETES AND THE FUNCTION OF INSULIN 
History 
Diabetes has been a medical problem for more than 2,000 
years. It was first recorded in the Ebers Papyrus from ancient 
Egypt as polyuria. Diabetes was also known in the far East where 
it was described by the great Chinese physician, Tchang Tchong-
King, in the year 200, as a disease of thirst. Later, the 
symptoms of polyphagia and polydipsia were added to polyuria as 
characteristics of this disease. The Arabian physician, Avicenna 
(980 to 1037), was the first to describe the association of 
diabetes with gangrene. His studies showed that individuals with 
diabetes had higher incidence of severe gangrene (75). 
Thomas Willis (88), in 1775, was the first European to 
recognize that glycosuria was associated with diabetes. He 
introduced the tasting of the urine as part of a qualitative 
examination, and found that it had a sweet taste, like honey or 
sugar. It was not until 1815 that Chevrel identified the sugar 
that had been found in the urine as glucose (87, 88). This was 
the same sugar that had been found in grapes. This work and that 
1 
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of Willis opened the door to innumerable observations on the 
subject and also helped set up a pattern of dietary treatment of 
the disease. 
Cawley, in the year 1788, was one of the first to 
associate diabetes with the pancreas. His work involved an 
autopsy on patients with diabetes and revealed that there had 
been severe damage to the canaliculi, as well as other pancreatic 
tissue (46). 
Another contemporaneous contribution to scientific 
knowledge was the anatomical study of the pancreas by 
Paul Langerhans (46). He discovered the islets of the pancreas, 
and it was this work that lead the French histologist, 
Gustave Laguesse, to suggest they have an endocrine function. He 
later named them "the islets of Langerhans" (56). It was not 
until 1889 that Minkowski discovered that the removal of the pan-
creas from animals produced diabetes. His associate, Joseph 
Von Mering, then reported this effect as being due to the lack of 
this organ's internal secretion (56). The changes found in the 
pancreatic tissue during diabetes lead Opie and Sobolev to 
advance the theory that diabetes resulted from pathologic changes 
in the islet tissue, that the islets were needed for control of 
carbohydrate metabolism and that the acinar cells were not. 
3 
In the summer of 1921, there was a culmination of the 
interest in the pancreas by the discovery of insulin by 
Fredrick G. Ganting and Charles H. Best at the University of 
Toronto. They proved the efficiency of this new substance, 
called insulin, by injecting it into diabetic patients and 
watching the blood sugar levels decrease. Further purification 
and concentration of the original extract was accomplished by 
J.B. Collip (63, 96). 
The years following this work could be ref erred to as 
the insulin era. With this new substance, the characteristics of 
hyerglycemia and glycosuria could be controlled. In 1936, 
Hagedorn discovered that the addition of protamine to insulin 
altered the solubility of the hormone and prolonged the duration 
of its effect (63, 64, 65). 
Since insulin was a protein, it was subject to 
digestion, and therefore, could not be relied on as an oral agent. 
In 1955, Franke, Achelis, and Betram developed the first 
practical oral hypoglycemic agent, 1-butyl 3-sulfonylurea. This 
compound, known as carbutamide, had the effect of lowering the 
blood sugar significantly. Although it was later found to be a 
toxic substance and was withdrawn from clinical use, it was the 
original compound that led to the development of the arylsul-
fonylureas (3). The most prominent of these oral hypoglycemic 
rr~· -----------~ 
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agents was tolbutamide, or Orinase, which was also found to lower 
blobd sugar levels. It functions by influencing the beta cells 
of .the pancreas to produce more insulin. 
The advent of orally effective drugs was important in 
the treatment of diabetes, because of the- ease with which they 
could be administered, and also because of the increased research 
that they have stimulated in this area. 
Carbohydrate Metabolism 
The ability of the body to utilize carbohydrates is 
known as carbohydrate tolerance. The failure in the metabolism 
of carbohydrates is the primary metabolic defect caused by 
diabetes. Diabetes mellitus is characterized by a decreased 
tolerance to carbohydrates evidenced by hyperglycemia, and by 
glycosuria, i.e. a high concentration of glucose in the blood and 
urine, respectively. These conditions may also be accompanied by 
defects that occur in the metabolism of fats. 
One of the most important reactions of glucose in 
mammalian tissue is the formation of glucose-6-phosphate through 
the action of the enzyme, glucokinase. This reaction, which is 
necessary for the further metabolism of glucose, has long been 
considered the site of hormonal control (28). Insulin has been 
known to accelerate the reaction in two ways: 1) by increasing 
J': ;: .--------------------------------------. 
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the rate of entry of glucose into the cell through the cell 
111embrane, and 2) by increasing the glucose-6-phosphate formation 
rate through action on the enzyme hexokinase. (Refer to 
Figure 1.) The glucose-6-phosphate can be converted into pyruvate 
and then into acetyl CoA, both in the liver and in muscle. In 
this way, insulin has been found to increase tolerance of the 
organism to carbohydrates. 
All attempts to associate insulin with the enzymatic 
reaction occurring in the cell had failed until Levine and Soskin 
(48, 50) demonstrated that insulin greatly enhances the uptake of 
glucose by the extrahepatic tissue at all levels of blood glucose. 
Later, Levine and Goldstein (87} postulated that insulin acts on 
the cell at the site of entry of the glucose, and thereby affects 
the rate of entry. This hypothesis was tested by the use of 
another sugar, galactose, upon which insulin was known to have a 
profound effect. Galactose is an isomer of glucose and will 
enter the cell, but will not be metabolized to any great 
extent (47). 
Other workers using tissues have confirmed the effect 
of insulin causing transfer of glucose into the cells. Insulin 
has been found to ·cause entry of glucose from the plasma into the 
humor of the eye. Arne and associates (95} have shown that when 
more than one sugar, whose entry into the cell is enhanced by 
~---··.... ---------------. 
FIGURE 1 
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iP-sµ~~n, ~re p~esent simultaneously, they appear to compete for 
th@ t!en.!?f~r sites. In alloxan diabetic animals, where the 
~!a~~t!c ~tate was achieved by alloxans destruction of the beta 
cells of ~he pancreas, glucose entry was found to be halved, but 
.,,,,. - -- -
after ~he ~dministration of insulin, it was found to return to a 
-- .... - -
normal level. Other studies have indicated that insulin more 
_ .. -- ~ ·- - - - - -
~h~~ g9ypJ~d the space through which radioactive galactose was 
~i§~!!PYt~d ~nto the tissues, and in this way, increased the rate 
@! g~~~Y (§0). There is also evidence that radioactive insulin 
@e~ p~~g~~ f!xed or bound to certain peripheral tissues, such as 
@ieph!~~~' ?~!pose tissue, and mammary glands. The amount of 
~!¥~9~@~ !9~m~d by such tissue after an addition of glucose, is 
@!!@~~iy p~9portional to the insulin which is bound (60). 
L~rid ~e~abolism 
~~~~yl coenzyme A acts in two ways in lipid metabolism. 
!~ !~ ~h~ pg!~ding block for the synthesis of fatty acids and the 
@~g p~9gµ9t of their breakdown. Although there is only one 
pathway for the breakdown of fatty acids, there are two for the 
~¥~~h~!?!~· These are the extramitochondrial pathway and the beta 
oxidation pathway in the mitochondria. The degradation of the 
te~~y ?~~ds occurs in the mitochondria with the same enzymes and 
~gf~c~9~s ~hat are used for the synthesis (28, 95) •. 
~------------------, 
' 
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Acetyl coenzyme A may also be converted into ketones. 
Ketone production occurs largely in the liver and is the result 
of acetoacetate being channeled through the Krebs' cycle for the 
production of energy. The ketones are readily utilized by both 
muscle and kidney. The production is usually kept at a moderate 
rate in the presence of an adequate supply of carbohydrate, but 
when there is an inadequate supply, the body turns to fat for 
energy. 
In the diabetic individual, there is an abnormal 
utilization of fat to meet the energy needs which are not 
supplied by the carbohydrate. The stores of fat in the adipose 
tissue are therefore depleted and there is a loss of weight on 
the part of the organism. It has therefore been found that in 
diabetes there are four abnormalities that occur in the lipid 
metabolism. There is a blockage of fatty acid synthesis and an 
increase in fatty acid oxidation. Further, there is a developmen 
of ketosis and also an increase in cholesterol synthesis. 
One of the first indications that there was an impair-
ment of fatty acid synthesis was demonstrated by Chaikoff (1). 
He showed that liver slices from alloxan-diabetic rats failed to 
synthesize fatty acids when· incubated in C-14 labeled solutions 
of fructose, glucose, lactate, pyruvate, or acetate. The 
administration of insulin to similarly treated animals restored 
the ability to synthesize fatty acids (89). 
10 
Siperstein was the first to suggest that NADPH was 
necessary in the mitochondrial synthesis of fatty acids. He 
showed that it acts as a hydrogen donor at each step in the 
elongation of the fatty acid chain (90, 95). Winegrad and 
Renold (89, 90), in their work, showed tnat insulin participates 
in the promotion of lipogenesis. Their hypothesis states that 
the NADPH, which was generated by the glucose metabolized in the 
hexose rnonophosphate shunt pathway, stimulated the lipogenesis. 
Gibson and Hubbard (26) measured the activity of two 
enzymes involved in the synthesis of fat by the extrarnitochondrial 
pathway. They found that acetyl coenzyme A carboxylase, which 
converts acetyl coenzyme A to rnalonyl coenzyme A, was not impaired 
in the diabetic animal, and that the sulfhydryl-containing enzyme 
that converts malonyl coenzyrne A to palrnityl coenzyme was greatly 
impaired. The impairment of this one enzyme may be sufficient to 
account for the reduction of fat synthesis in the diabetic. 
Ketosis 
This is a condition that is associated with a high rate 
of fatty acid oxidation, during which the liver produces consider-
able quantities of ketone bodies. The ketone bodies are aceto-
acetate, beta-hydroxybutyrate, and acetone. All of these are 
found to stern from acetoacetyl coenzyme A (29). 
11 
It has already been stated that ketosis arises when 
there is an inadequate supply of c~rbohydrates and the body turns 
to fat as a source of energy. Large amounts of acetyl coenzyme A 
' are produced from the breakdown of fat which leads to increased 
ketone production. In the diabetic state, the rise of ketone 
bodies can be attributed to the lack of insulin and, therefore, 
an inability of sufficient carbohydrates to enter the cell. 
There is then an acceleration of the utilization of fatty acids 
for energy purposes, a result which causes an increased ketone 
production (24). 
Cholesterol 
Cholesterol arises in the body mainly by synthesis, but 
some can be provided by the diet. It can be eliminated by a 
conversion to bile acids, or it can be excreted as neutral sterol 
in the feces. The liver is the main site of cholesterol synthesi 
and acetyl CoA is the main source. Cholesterol in the diet is 
absorbed from the intestine, and along with other lipids, is 
incorporated into chylomicrons and lipoproteins (28) • 
Many investigators have demonstrated a correlation 
between serum lipid levels and the incidence of coronary heart 
disease and atherosclerosis. Of these lipids, cholesterol has 
been found to exhibit a high degree of correlation. 
,;--------------, 
~~'.. 
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Liebow and Hellerstein have shown conclusively that a 
definite increase in the .incidence of atherosclerosis accompanies 
,. 
diabetes (52). Studies by Windaus (91) and Schonheimer (67) 
showed that, in atherosclerotic arteries, there was an increased 
content of cholesterol. 
Hotta and Chaikoff (9) , by their studies on liver 
slices from diabetic rats, have shown that cholesterol synthesis 
is increased. The liver slices were studied by measuring the 
cholesterol after incubation with C-14 labeled acetate. 
Further work by Warren and associates (83) has shown 
that out of 484 persons surveyed with these diseases, only four 
did not have both. This universality of atherosclerosis in 
diabetes is true for both young and old, male and female (83). 
Finally, Joslin has shown that the frequency and the 
severity of atherosclerosis in diabetes is correlated with long, 
uncontrolled glycosuria, hyperglycemia, hyperlipemia, and 
hypercholesterolemia (35). 
Protein Metabolism 
Protein metabolism, like fat metabolism, is secondarily 
affected through a direct effect of insulin on the utilization of 
glucose. In the diabetic state, there is a loss of protein due 
to two influences on protein metabolism: 1) there is an 
~-------------------, 
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excessive catabolism by the body in order to generate glucose 
from ainino acids, and 2) there is a failure of the body to 
rebuild the protein· that has been broken down. Insulin has, as 
one of its main functions, the furnishing of glucose for energy 
purposes, and therefore, there is no need for protein catabolism 
when the supply of insulin is normal. Proof of this has been 
indicated by the fact that plasma amino acid levels fall after an 
injection of insulin into a diabetic animal (42). 
Krahl, in his work, tried to show that peptide synthe-
sis is inhibited in diabetes, in both liver and muscle. He 
demonstrated that after administration of insulin to a diabetic 
animal, the tissues were found to exhibit an increased protein 
synthesis (44). Krah! and Sinex (71) demonstrated that the 
incorporation of C-14 glycine or C-14 alanine into protein of 
rat diaphragm was enhanced by insulin in the absence of glucose 
in the incubation medium. This seems to indicate that the 
stimulation of amino acid incorporation by insulin into muscle 
occurs by a mechanism other than through stimulation of glucose 
transport. 
Krahl studied the incor~oration of amino acids in liver 
slices. He postulated that no direct effect in vitro of insulin 
could be demonstrated with slices from the most severely diabetic 
animals. Insulin injections administered ten hours before the 
~-------------------~ 
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start of the experiment were found to restore normal incorpo-
ra~ion (43, 44) ~ 
.. 
Krahl and Penhos (43) repeated these experiments using· 
liver slices from both normal and partially depancreatized rats. 
The results indicated that insulin stimulated amino acid 
incorporation into liver protein and that the effect on liver 
slices from fasting animals depends on the presence of glucose. 
Finally, the results showed that the stimulation is greater with 
liver slices from mildly diabetic animals than with slices from 
either normal animals or severely diabetic animals. This effect 
was demonstrated to reach a maximum in approximately two to 
three hours after the administration of insulin. 
~-------------------~ ~; 
CHAPTER II 
.. 
THE CHEMISTRY AND THE PROPERTIES OF HEXOKINASE · 
History 
The enzyme, hexokinase, was first described by Meyerhof 
in 1927. He obtained an activator from yeast which restored to 
aged muscle its lost ability to ferment glucose (57). 
In 1935, through the experiments of Von Euler and 
Adler, it was found that there was an enzyme in yeast which 
catalyzed the transfer of phosphorous from adenosine triphosphate 
to the hexoses. This enzyme was first called heterophosphatase, 
but the name was later changed to hexokinase (79). 
In 1941, Colowick and Kalckar showed that the terminal 
phosphate group of ATP was transferred to the hexose and 
demonstrated that the primary products of the reaction were 
adenosine diphosphate and hexose-6-phosphate. 
It was later discovered that glucose, fructose, and 
mannose are all acted upon by the enzyme, but the rate of 
phosophorylation varies with the sugar used (14). 
Berger, Slein, Colowick, and Cori, and also Kunitz and 
McDonald, demonstrated methods of isolation and properties of 
hexokinase from baker's yeast in 1946 (45). 
15 
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The manometric method described by Colowick and Kalckar 
was one of the first adopted for the measurement of hexokinase 
- . . 
.. 
activity. This method was based on the f_act that one equivalent 
of acid is liberated per mole of phosphate transferred i·n the 
reaction (14). 
In 1932, Slein was the first to propose the existence 
of multiple forms of this enzyme. He suggested that there was a 
species with a relatively high km for glucose and a limited 
hexose specificity. He called this type glucokinase (72). 
The following studies conducted by Ballard and 
Oliver (5), and Niemeyer and Weinhouse (59, 70) have shown that 
the glucokinase varies in activity depending on the physiological 
condition of the animal. Katzen's studies have suggested that 
there is a further breakdown of the enzyme into multiple forms, 
and that these forms can be found in adipose tissue, brain tissue, 
muscle, testes, and the liver (36, 37, 38). 
Chemistry 
Phosphoryl group transfer enzymes, by definition, are 
those that catalyze the transfer of phosphoryl groups from a donor 
molecule to an acceptor. The phosphoryl groups appear as follows: 
0 
t 
-P-OH 
I 
OH 
~---~ -------
? 
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Phosphoryl group transferring enzymes may be placed under six 
subclasses: 1) kinases or transphos~horylases, 2) pyrophos-
phokinases, 3) phosphomutases, 4) certain pyrophosphorylases, 
5) phosphatases, and 6) miscellaneous. The kinases are those 
enzymes that catalyze the transfer of phosphoryl groups from any 
nucleoside triphosphate and constitute by far _the largest of 
these classes. The reaction involved consists of an attack by 
the acceptor molecule on the terminal phosphorous atom of the 
nucleotide (45). 
0 0 0 
1 ' f Nucleoside-O-P-O-P-O-P-0 
I I I 
o- o- o-
0 0 
1 i 
Nucleoside-O-P-0-P-O 
I I 
o- 0-
+ R-0-H 
0 
II 
+ R-o-P.:..o 
I 
0 
Hexokinase has been found to be a tetramer of molecular 
weight 96,000 at a pH of 5, and can be dissociated into four 
inactive subunits {mol. wt. 24,000). This dissociation can be 
accomplished by acid or alkali, and the subunits can reassociate 
and full activity returns upon neutralization when oxidation of 
the SH group is prevented. In neutral solutions, the modified 
enzyme exists largely in the dimer form. The dimer has a 
r.----------------~ -k' 
18 
molecular weight of approximately 48,000 at a pH of 8. The 
unmodified enzyme exists largely as ~ tetramer at low ionic 
strength but is converted to the dimer at high ionic strength or 
in glucose. 
In 1967, Schulze separated yeast hexokinase into 
several forms. From the crude extract, he found only one chroma-
tographic form. After ammonium sulfate percipitation, the enzyme 
could be separated into two chromatographic forms P-I and P-II. 
These forms further broke down into forms P-III and S and 
occurred after a storage of the enzyme for a period of time. 
When the enzyme was treated with trypsin for -0 minutes, S forms 
were produced. These were more acidic and required a salt 
gradient for elution from the DEAE-cellulose column (68). 
Amino acid composition of the various forms of hexo-
kinase is shown in Table I (25). The values are expressed as 
moles per mole of dimer. 
In this case, the dimer was assumed to be catalytically 
active. To calculate the amino acid composition of the S forms, 
the molecular weight was assumed to remain that of the dimer, 
even though the treatment with trypsin to get the S form caused 
the release of several peptides. 
Boyer, in 1954, using p-hydroxymercuribenzoate, and 
Ellman, in 1959, using 5.5-dithiobis (2-nitrobenzoic acid) did 
TABLE 1 19 
AMINO ACID COMPOSITION OF VARIOUS FORMS OF HEXOKINASE 
Moles per Mole Protein 
S-carboxymethyl cysteine 
Aspartic acid 
Threonine 
Serine 
Glutamic acid 
Pro line 
Glycine 
Alanine 
Valine 
Half cystine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Lysine 
Histidine 
Arginine 
p..,.J 
3.6 
49.4 
26.3 
22.0 
45.3 
21.3 
37.4 
30.5 
26.0 
0.85 
0.98 
28.0 
38.8 
14.7 
16.2 
33.5 
08.4 
14.7 
.(M.W. 48.000) 
P-II 
2.8 
48.8 
25.9 
20.6 
47.6 
24.5 
35.8 
29.9 
21.1 
00.0 
09.7 
31.9 
31.7 
14.1 
20.7 
31.5 
04.8 
16.7 
S-I 
o.o 
50.0 
25.7 
20.1 
46.4 
21.1 
36.0 
27.4 
23.3 
03.3 
10.2 
26.3 
41.7 
14.2 
16.7 
34.0 
06.7 
15.8. 
S-II 
o.o 
47.6 
26.1 
20.5 
48.3 
24.6 
36.3 
29.4 
19.7 
03.1 
10.4 
33.4 
32.0 
14.1 
22.0 
30.9 
03.8 
17.1 
L-------------1 
" 
~.· 
20 
sulfhydryl determinations on forms P-I and P-II. At all of the 
pH values, 7 through 11.5, both form~ of the enzyme showed.the 
presence of three sulfhydryl groups per dimer. ·However, later 
studies showed that P-I contains four SH groups per dimer, one 
of which can be titrated only in the presence of a denaturing 
agent, while the other form P-II contains only three SH 
groups (7). 
The terminal amino acid on the carboxy end can be de-
termined by incubation with carboxypeptidase A. The reaction 
was carried out in 0.2 M NH4Hco3 . The amino acids that were 
liberated were determined by amino acid analysis after the 
protein was precipitated with trichloroacetic acid. The results 
of this experiment showed that both of the P forms appear to have 
an alanine residue as the carboxy terminal amino acid and form S 
appears to be very similar to P-II. This suggests that the 
trypsin modification does not occur at the carboxy end. These 
results are indicated in Table II (25). 
Studies on the amino terminal by the Edman degradation 
method indicated that the most prevalent amino acids were glycine 
and valine. These were found to be 0-5 to 0.7 moles each out of 
a total of 2 to 3 moles per mole of dimer (25) • 
Properties 
Crystalline yeast hexokinase has been found to catalyze 
TABLE II 21 
AMINO ACID RELEASE UPON INCUBATION WITH CARBOXYPEPTIDASE A 
,. 
Moles per Mole of Protein (M.W. 48,000) 
), Form P-II P-II P-I P-I S-II 
Hours of Incubation 17 23 11 15 '16 . 
Alanine 1.86 2.12 2.40 2.86 1.90 
Leucine 0.84 1.50 1.06 1.36 1.72 
Valine 0.7~ 1.12 0.76 1.02 1.08 
Isoleucine 0.70 1.08 0.72 1.02 
Threonine 0.50 0.68 1.20 1.46 1.00 
~---------' 
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the phosphorylation of D-mannose, D-glucose, and D-fructose, and 
alsq the. conversion of D-glucosamine to D-glucosamine-6-phosphate .. 
It can also. act on 2-Deoxy-D-glucose, but has no effect on 
L-arabinose, D-g~lactose, ·suc~o~e, D-lactose, maltose, trehal6se, 
raffinose, D-xylose, or L-rhamnose. 
The enzyme is a protein of the albumin type and has an 
isoelectric point between pH 4.5 and 4.8. The composition was 
determined as follows: C, 52.16; H, 7.08; N, 15.62; P, 0.11; 
S, 0.91; and ash, 0.36. It is most stable a- a pH of 5 and has a 
broad optimum for activity between pH 8 and 9. 
The catalytic action of hexokinase requires magnesium 
f ions which act as activators. It is also irreversibly in-
~- activated by mustard gas and inhibited by SH reagent. Work done 
i 
' t·· by Berger (25, 66) has shown that the thiols act as reactivators 
after inactivation. Trypsin has also been found to cause 
inactivation whereas chymotrypsin has not. 
Recent studies have focused on hexokinases taken from 
animal tissues. Hexokinase has been found in brain, kidney, 
liver, heart, muscle, and testes.. Animal tissues have been found 
to contain multiple forms of hexokinase. In work by Katzen (36, 
38), these have been designated as types I through IV on the 
basis of their electrophoretic mobilities. Type IV hexokinase is 
also known as glucokinase and is found primarily in the liver. 
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It has a km for glucose of 1 - 2 X lo-2. Type III has been found 
primarily in the liver, but traces of it are also found in the· 
' 
kidney, adrenal glands and fat pad, as well as all other tissue. 
Skeletal muscle has been found to consist primarily of type II, 
but it and type I have been found in all other tissue. Type I 
through type III have km values for glucose of 4.5 X lo-5 for 
type I, 2.3 X lo-4 for type II, and 7.0 X lo-6 for type III. 
Pilkis and Krahl (97) conducted studies on the molecu-
lar weight of hexokinase from rat liver and found it to be 
96,000 for hexokinase and 48,000 for glucokinase. 
All hexokinases have a similar, broad pH optimum of 
7.8 to 8.8. 
One of the most important properties of the hexokinases 
is their inhibition by glucose-6-phosphate and the reversal of 
this process by inorganic phosphate. This is considered 
important in the regulation of glucose phosphorylation in the 
intact cell. 
CHAPTER III 
THE ORAL HYPOGLYCEMIC AGENTS 
History 
The earliest successful form of treatment of diabetes 
was through the use of insulin. Insulin is a protein consisting 
of two polypeptide chains. The A chain contains 21 amino acids 
with glycine at the amino end and asparagine at the carboxy end. 
The B chain consists of 30 amino acids with phenylalanine at the 
amino end and alanine at the carboxy end. The two chains are 
held together by disulfiqe bonds (62, 64). 
Since insulin is a protein it can be readily attacked 
by proteolytic enzymes present in the digestive system. Studies 
by Harris and Li (30) have shown that insulin, when subjected 
to carboxypeptidase for 6 hours lost 20 per cent of its biologica 
activity. Further studies by Smith (74) have shown that leucine-
amino peptidase attacks the insulin structure at the amino end 
and causes some loss of activity. 
From work such as this, it is evident that insulin can-
not be administered orally and therefore the search for success-
ful -oral hypoglycemic agents must continue. 
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FIGURE 3 
STRUCTURE OF INSULIN 
A.Cha.in 
Glycine 
Isoleucine 
Valine 
Glutamic Acid 
S--- Cysteine 
Cysteine ---
Alanine 
Serine 
Valine 
S--- Cysteine 
Serine 
Leucine 
Tyrosine 
Glut amine 
Leucine 
Glutamic Acid 
Asparagine 
Tyrosine 
Cysteine ---
Asparagine 
s-s----
S- S---
B·chaiti 
Phenylalanine 
Valine 
Asparagine · 
Histidine 
Leucine 
Cysteine 
Glycine 
Serine 
Histidine 
Leucine 
Valine 
Glutamic Acid 
Alanine 
Leucine 
Tyrosine 
Leucine 
Valine 
Cysteine 
Glycine 
Glutamic Acid· 
Arginine 
Glycine 
Phenylalanine 
Phenylalanine 
Tyrosine 
Threonine 
Pro line 
Lysine 
Alanine 
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In some countries, certain plant extracts have been 
employed in the treatment of diabetes. These drugs were. found.- to 
be effective, but in varying degrees. Miller (58) and Clement 
(13) worked with alkaloids derived from plants. Miller found 
that the galepine plant extract had the property of reducing 
blood sugar levels in both the diabetic and normal individual. 
Clement showed the same result with the lapamine plant. Insulin-
type agents were also found in some bacteria. Levine and Best 
(53) were the first to isolate such an agent, but it was not 
utilized because of its high hepatotoxicity. 
The Sulf anilamides 
In 1925, the synthalins were tried as an effective oral 
~gent in the treatment of diabetes, but these were found to be 
inadequate because of their toxicity. Between 1939 and 1942, 
work was conducted on the compound, isopropyl thiazol. This drug 
was found to lower blood sugar levels, and attempts were made to 
associate the chemical structure of this compound with its 
hypoglycemic action (54). The results of these investigations 
were that such an effect was found in the p-amino-benzene-
sulphon_amide-thiodiazol group. Later studies indicated that this 
drug had an effect on the a~cells of Langerhans. It was found 
that these cells were destroyed, and this was postulated as the 
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reason for the hypoglycemic action (80). 
_ In 1955. (19), the .compound ,l-butyl-3-sulfot1.ylurea, or. 
carbutamide, was developed in Germany. This drug was used for· 
the long term treatment of diabetes, but was found to be 
effective only in patients with mild forms of the disease. It 
was also a far more active agent than isopropyl thiazol (2254RP). 
References to tolbutamide, or N-(p-toluenesulfonyl)-
(n-butyl)urea, first appeared in the literature in 1956. The 
main activity of this substance was its effect on the S-cells of 
the pancreas, which it stimulated to release more insulin (55). 
Structure of Sulf anilamides 
. The sulfanilamides may be classified into two groups 
according to whether they are related to urea or thiodiazol. 
These compounds are actually aryl-sulf anilamides because they 
have an aromatic nucleus (93). 
Studies have shown that all of the sulfanilamides 
possess the following .properties. They stimulate the S-cyto-
trophic action, and they stimulate the formation of new S-cells. 
The general formula for the sulfanilamides can be 
~xpressed as: 
R1- so2- NH- w-Y-i2 
x-----
.. 
. ·. 
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The X and Y stand for alternate atoms in the sequence O, S, and 
N. ·The radical _groups R1 . an~ R2 ca!l vci,ry .to. a gr~at. deg.ree. _ .. 
Isopropyl thiazol, or. compound 2254RP, .was investigated 
in 1944. Its isopropryl radical was replaced by substitutions 
of any of the following: CH3 , c 2H5 , C4H9(n)' .c3~7 (n) ' or 
C5Hll(n) 0 All of these newly formed compounds were found to 
possess a hypoglycemic activity (92) • 
Tolbutamide 
Tolbutamide, or N-butyl-N'-p-toluenesulfonylurea, was 
discovered in 1956. It is a compound similar to carbutamide and 
can be administered intravenously, subcutaneously, or orally. 
Tolbutamide dissolves readily in water and forms easily-soluble 
alkaline salts. 
About 40 to 45 per cent of the tolbutamide that is 
administered is bound to serum albumins. It has a short half 
life because of its weak binding, and therefore, most of it 
remains in an unchanged form and only small amounts are 
decarboxylated (98), a reaction which occurs in the liver and 
kidney (95). 
Studies have shown that about 80 per cent of a 3 gram 
do$e of tolbutamide in humans will be excreted within 48 hours 
(98). The carboxylated form of the drug has been isolated from 
the urine. This form can be percipitated in urine at a pH of 5. 
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SULFONYLUREAS 
-
Compound Structure 
Carbutamide 
Tolbutamide 
Chloropropamide 
/c=c, 
Cl-C~ C-S0 2NHCONH(CH2) 2CH3 ~c-c" 
c=c c-c 
/ \ / ' CH3-c C-S02NHCONH-C C ~c-c; 'c-c/ 
Methahexamide 
/c=c, /c-c, 
Acetohexamide CH -CO-C C-SO NHCONH-C C 
3 ~ ~ 2 ' / C-C C-C 
C=C C-C 
/ ' / ' CH3-S-C C-S02NHCONH-C C ~ # ' I c-c c-c 
Thiohexamide 
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The carboxylation of tolbutamide occurs in the p-posi tion·, and 
the final degradation products are p-toluenesulfonylurea and 
,, .• 
p-toluenesulfonamide (See Figure4). 
The mode of action of the sulfonylureas, especially 
tolbutamide, can be explained in terms of the effects of these 
drugs on the pancreas. The sulfonylureas stimulate the release 
of insulin reserves present in a readily soluble fo~. This is 
accompanied by both mobilization of the insulin bound to granules 
and reactive insulin regeneration. Secondly, this process is 
stimulated by each new administration of tolbutamide. Thirdly, 
. . 
there is produced ~ refractory period, following the ~rimary 
administration and activation of ,the S-cells, which allows the 
blood-glucose levels to return to normal. 
Insulin secretion caused by the sulfony~ureas was 
studied both in vivo and in vitro. As early as 1946, the 
pancreatic venous blood of dogs was examined for the hypoglycemic 
factor after an administration of 2254RP(IPTD) and resulted in 
the finding of a blood sugar lowering factor present in the 
. . . 
pancreatic vein. Similar studies conducted before and after 
administration of sulfonylureas showed that glucose uptake was 
increased and that the levels of insulin doubled (ll, 33, 98)~ 
The sulfonylureas have· some effect on the liver tissue, 
but hypoglycemia is not depresse~ or inhibited by hepatoectomy. 
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FIGURE 4 
METABOLISM OF TOLBUTAMIDE 
_;,C=C\ 
CH3-c~ ~C-S02NHCOH2 ~c-c~ 
p-Tolylsulfonylurea 
1c=c, 
CH3-C C-S02NHCONBu ~C-C~ 
Tolbutarnide 
· C=C 
/ \ COOH-C~c-c'C-S02NHCONHBu 
n-Butyl-n-p-carboxyphenyl-
sulfonylurea 
,. 
C=C 
/ ' CH3-c~ C-S02NH2 ~c-cf' 
p-Toluenesulfonarnide 
C=C · 
I \ 
HOH2C-C C-S02NHCONHBu ~c-c? 
n-~utyl-n-p-hydroxy-rnethyl­
phenyl-sulfonylurea 
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Recent work has indicated that tolbutarnide will induce a 
per-?-.ph,era+ glucose uptake in hepatec~omized animals. In normal .. 
. animals, hypoglycemia is due to hepatic retention of glucose,·a 
.. marked increase in glucose uptake, or significant decrease in 
hepatic glucose output (98). 
The sulfonylureas exhibit an effect on the carbohydrate 4 
fat, and protein metabolism. The single most important factor in 
carbohydrate metabolism is blood-glucose. In·the normal animal, 
glucose levels have been found to drop 75 per cent of their 
original value in approximately 2 hours, whereas in the diabetic, 
the blood-glucose lowering activity proceeds very slowly after 
administration of the sulfonylureas. This decrease in the blood-
sugar levels may be accounted for by the increase in peripheral 
glucose utilization or by inhibition of glucose production by the 
liver (98). 
Animal experiments with isolated liver tissue have 
suggested that the sulfonylureas inhibit phosphorolysis via the 
stimulation of endogenous insulin secretion. Further, there is 
also an increased oxidation of glucose due to the action of 
glycolysis and the citric acid cycle. Other studies showed that 
there was no effect on lactate and pyruvate production (20, 24, 
98) • 
Henes and Wachenberger (31) have shown that a-keto-
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glutaric acid, an intermediate of the Krebs' cycle and a 
substance which plays a key role in ;Lipid and protein metabolism, 
is elevated by tolbutamide and decreased by insulin. 
Protein metabolism is only slightly affected by 
tolbutamide. Studies have indicated that there is a 20 per cent 
decrease in a-amino nitrogen after an intravenous administration 
of insulin and an 80 per cent decrease after administration of 
tolbutamide. There is also a decrease in the free amino acids 
in the blood. Despite these facts, the sulfonylureas have been 
found to increase the synthesis of peptides and proteins 
slightly (20). 
The lipid metabolism is influenced secondarily by the 
action of the sulfonylureas on the carbohydrate metabolism. 
These drugs stimulate the incorporation of glucose into fatty 
acid tissue, but at a slower rate than would be facilitated by 
insulin (20, 23). 
Guanidines 
In 1918, Watambe demonstrated that high levels of 
guanidine in the blood induced low blood-glucose levels, or 
hypoglycemia, in parathyroidectomized rabbits (84, 85). 
Later studies indicated that the hypoglycemic action 
of guanidine was inversely proportional to the amount of 
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GUANIDINE AND DERIVATIVES 
Compound· Structure 
NH. -C-NH 
. 2 11 2 
NH 
Synthalin A NH2-~-NH(CH2)10NH-fi-NH2 
NH NH 
Synthalin B NH2-W-NH(CH2)12NH-~-NH2 
NH NH 
Phenethylbiguanide 
r=c, 
C~ . /,C-(CH2) 2NHCHNHCNH2 ~-CQ' .. ilhi Mir 
Hypoglycine A CH3-c -C-CH -CHCOO-'~/ 2 I ~ . NH 
Hypoglycine B CH~-C~C-CHNHCO(CH2) 2CHCOOH 
.tJ 'c/ I I 
. COOH NH
2 
/~ CH -CH -CH -CH -NH-C C-NH 
2 2 2 2 !hi ~ 2 N1-n-butyl-biguanide 
N1-dimethylbiguanide 
!· 
! 
I 
'• 
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Later studies·conducted with these biguanides indicated that: they 
-had the same blood-sugar level lowering effect as the guanidines. 
Substitutions for groups R1 and R2 lead to stronger and more 
effective preparations, whereas substitutions for the R3 and R4 
group produced drugs that were ineffective and possibly toxic. 
Effective substitutions for R1 and R2 were classed only in the 
lower alkyl groups, such as CH3 , -c3a7 , -c5a11 , and -cH3-cH=CH2 • 
In 1955, Unger and Freedmann found that substitutions 
of arylalphatic radicals for R1 and R2 produced relatively 
effective hypoglycemic compounds (77). Similarly, thiopene or 
furan were found to form useful hypoglycemic compounds in such 
substitutions. 
Phenethylbiguanide 
The compound, phenethylbiguanide, first appeared in a 
clinical evaluation in 1956. Along with dimethylbiguanide and 
n-butyl biguanide, it w~s found to possess a profound hypo-
glycemic effect. Shortly thereafter, the drug was quickly 
adopted for extensive clinical use in the treatment of diabetes. 
Best results in treatment were achieved by intravenous adminis-
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tration of 10 to 15 mg per kg of body weight (98) • 
. Rec~ntly cond'l;lcted studies have indicated . that there .. 
' 
are side effects, such as increased blood pressure and 
respiratory depression. Doses greater than 10 mg per kg have 
been found to antagonize adrenaline levels, but have no effect 
on histamine or acetylcholine (8). 
Phenethylbiguanide belongs to the group of compounds 
known as the biguanides. Structurally it possesses a benzene 
ring and two guanidine groups and can be represented as follows: 
,. c=c, 
C C- CH2-CH -NH-C-NH-C- NH 'c-c~ 2 11 II 2 
NH NH 
The mode of action of phenethylbiguanide differs 
significantly from that of tolbutamide. There is no requirement 
for any pancreatic tissue. Hypoglycemia is produced by 
increasing the uptake of glucose by the tissues. There is a 
decrease in the amount of muscle glycogen and a marked increase 
in lactic acid production. Further, there is a decrease in the 
consumption of oxygen, and this, therefore, suggests that 
phenethylbiguanide functions by stimulating anaerobic glycolysis. 
The ability of the biguanides to lower blood-glucose 
levels has been attributed to a number of causes. Studies 
conducted in vivo and in vitro indicate that these drugs are able 
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to lower blood-sugar in ketoacidosis in a diabetic who is 
presUllledly wi tbout insulinogenic cap~city (56, 84, 98). Their. 
function appears to be an enhancement of the action of the 
insulin that is availabie in the cells and which was previously 
unresponsive. Secondarily, the biguanides appear to stimulate 
the oxidative utilization of glucose. Consequently, as the blood 
sugar levels decrease, there is a lowered secretion of insulin. 
This, then, causes an increase in fatty acid and glycerol 
mobilization from the adipose tissue. Unlike insulin, the 
biguanides lack the ability to depress lypolysis and, therefore, 
promote lipogenesis (Q6, 98). 
Studies on the metabolism of phenethylbiguanide 
indicate that it is metabolized at least in part and excreted as 
the glucuronide of its parahydroxy metabolite, para-hydroxy-
phenethylbiguanide (94). 
Biguanides, following an oral administration, cause a 
slow, gradual fall in the blood-sugar in both the normal and 
diabetic patient. Such a decline requires a period of about five 
hours. In the case of phenethylbiguanide, it has been suggested 
that the hypoglycemic response reflects the entry of unmetabo-
lized drug into the cells, and then the metabolic alteration of 
the drug which causes a change in permeability of the cell to 
glucose. 
CHAPTER IV 
• 
MATERIALS AND METHODS 
Reagents 
The following reagents were utilized during the course 
of all experimental procedures. 
Comeounds: 
Adenosine-5-triphosphate, disodium salt, Sigma grade. Sigma 
Chemical Companu, Saint Louis, Mo., lot No. 14B-71090, 
lOC-7190 
Magnesium sulfate, Mallinckrodt Chemical Company, Saint Louis, 
Mo., lot No. 6070 
Potassium chloride, Mallinckrodt Chemical Company, Saint Louis, 
Mo., lot No. 6558 
Trizma base, Sigma grade, Sigma Chemical Company, Saint Louis, 
Mo., lot No. 94B-5020 
Dextrose, Mallinckrodt Chemical Company,. Saint Louis, Mo., 
lot No. 4912 
Glucose-6-phosphate dehydrogenase, Sigma Chemical Company, 
Saint Louis, Mo., lot No. lSB-7240, 78B-7610-2 
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Nicotinamide adenine dinucleotide, prepared from yeast, Sigma 
grade III" S.igma Chemical Company, ~aint Lou.is, .Mo., 
.. 
. lot No. SOC-7210 
Hexokinase, prepared from yeast, Sigma grade, Sigma Chemical 
Company, Saint Louis, Mo., lot No. 105-625 
Sodium chloride, crystals, Mallinckrodt Chemical Company, 
Saint Louis, Mo., lot No. 7581 
Sodium hydroxide, analytical reagent, Mallinckrodt Chemical 
Company, Saint Louis, Mo., lot No. 7708 
Barium hydroxide, baker's analyzed, Baker Chemical Company" 
Phillipsburg, N. J., lot No. 1094000 
Glucostat, prepared enzymatic glucose reagent, Worthington 
Biochemical Corporation, Freehold, N. J., lot No. SKA 
Drugs: 
Alloxan, Matheson Coleman and Bell Company, Norwood, Ohio, lot 
No. 1147 AX 535 
Pnenethylbiguanide, u.s.v. Pharmaceutical Corporation, Yonkers, 
New York, lot No. CUN~A~l48 
Tolbutamide, The Upjohn Company, Kalamazoo, Michigan, lot 
No. 11584-4 
Sodium Azide, Matheson Coleman and Bell,- Norwood, Ohio, lot 
No. SX299-2781 
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Insulin, bovine pancreas, Calbiochem Corporation, Los Angeles, 
California, lo~ No.. 53256 
Nembutal, Sodium, Abbott Laboratories,.North -Chicago, Illinois, 
lot No. ·3117 
Preparation of Animals 
Holtzman male rats weighing between 200 and 350 grams 
were fed on a normal diet. These animals were separated into 
two groups, normal and diabetic, and were treated with tolbu-
tarnide, phenethylbiguanide, and insulin. The diabetic state was 
achieved by the administration of the diabetogenic drug, alloxan •. 
The administration of the drugs was accom~lished by 
interperitoneal injection of the specified doses. Alloxan was 
administered at a dose of 60mg/kg of animal weight, phenethyl-
biguanide at O.lOrnM/150 grams of animal weight, tolbutamide at 
0.35rnM/150 grams of animal weight, insulin at 0.3 units/ml/kg of 
animal weight, and saline solution in equimolar amounts (6, 15, 
16, 17). 
The animals were decaptitated at different intervals 
after injection of the drugs. Some were used six hours after 
administration, some at twelve, and others at twenty-:-four. 
Tissue Preparation 
After decapitation, the liver was quickly removed and 
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weighed. One gram samples were carefully removed and homogenized 
at two degrees centigrade in a Po.tter-Elvehjem. homogenizer, in _ -. 
- . 
two volume.s of cold.0 .. 15M potassium chloride, 0.004M magnesium 
sulfate·, 0.004M EDTA, and o .. 004M N-acetyl cystein pH 7.0. The 
homogenate was then-centrifuged, at 13,400 revolutions per minute 
for twenty minutes, in the Sorvall superspeed centrifuge. The 
supernatant was then removed and placed in the Spinco Model L 
centrifuge for ~ighty minutes, at 100,000 x g. The pink super-
natant was then removed·and found to have a_hexokinase activity 
of 2 to 3 units/ml at 25 degrees centigrade (2, l'S, 34, 37). 
The Assay Method 
A wide variety of methods for the determination of 
hexokinase and glucokinase activity are available, but the most 
satisfactory method appears to be that of DiPietro and 
Weinhouse ( 18, -81) • In. this method, the product of the reaction, 
glucose-6-phosphate, is _rapidly 6.xidized by NADP+ in the pre-
sence of glucose-6-phosphate dehydrogenase. The formation of 
NADPH can then be followed spectrophotometrically at 340 
nanometers. 
The supernatant, prior to use in the assay method, was 
passed through a column of G-25 Sephadex. Sampl~s were collected 
and assayed for hexokinase and glucokinase activity. Each sample 
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consisted of 0.1 ml of supernatant and was added to a 1 cm. 
light- pat;l:l 9uvette with the following. reagents: ... 5. 8 ml of 0. lM 
Tris~.c1 buffer, 0.15 ml. of 0.075M magnesium sulfate, O.l ml. of 
·Q"~007SM NADP, 0.1 nil of 0.075 ATP neutralized to.pH 7.o;·o.i5 ml. 
of l •. OM potassium chloride, 0.2 ml. of 0.75M glucose, 0.4 ml. of 
glucose-6-phosphate dehydrogenase, diluted to contain 40 units/ml 
Since the crude preparation contains both glucokinase 
and hexokinase activity, hexokinase can be assayed by altering 
the glucose concentration in the assay procedure to 0.00375M. 
Glucokinase can then be corrected for by subtracting the activity 
measured with 0.00375M glucose, from that measured with 0.75M 
glucose. Further, all of the readings were corrected for low 
optical density by subtracting the observed increase, measured 
with all of the reagents except ATP (18, 61, 66, 81, 82). 
Definition of a Unit 
A change in optical density of 4.14/minute corresponds 
to a glucokinase activity of one micromole of glucose phos-
phorylated per minute when only one mole of NADP is reduced per 
mole of glucose phosphorylated (81). 
One unit of activity is defined as the amount of enzyme 
catalyzing the-phosphorylation of one micromole of glucose per 
minute at 28 degrees centigrade. 
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E_reparation of the Diabetic State 
Male Holtzman rats we.re fasted for twenty-four hours. 
,. 
After fasting,_ they were weighed. and injected with 60 mg/kg -of 
. . I 
animal weight of alloxah. These animals were then fed for two 
days and fasted for twenty-four hours prior to taking a sample 
for glucose determination. Samples were collected by cutting 
the tail vein and allowing the blood to flow into a microtube. 
Blood Glucose Determination 
To insure that the animals were sufficiently diabetic, 
blood sugar levels were measured. Levels of 200 mg per cent or 
more were considered to be adequate for all experimental 
, procedures . 
'~ . 
Two microtubes of blood were collected from each animal 
Each sample was then centrifuged for four minutes in the Beckman 
microfuge, and the serum was removed. Ten microliters of the 
serum were then added to 180 microliters of 0.08N barium 
hydroxide and 40 microliters of 5 per cent zinc sulfate. This 
mixture was then centrifuged for one minute and 40 rnicroliters 
of the supernatant were removed. A blank and standard were 
prepared by utilizing 40 microliters of water and 40 microliters 
.of a 9.9 mg per cent glucose solution. To each of these, the 40 
microliters of serum and solution. To the 40 microliters of 
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serum and solution, the 40 microliters of water, and the 40 
microliters of.glucose.standard, was added 200 microliters of 
Glucostat at o.ne minute intervals. Glucostat.is a co.upled enzyme 
\ 
system utilizirig.glucose-oxidase-peroxidase and a chromogen-o-
dianisidine which oxidizes true glucose to gluconic acid and 
hydrogen peroxide. The reactions were allowed to continue for 
seven minutes at 25 degrees centigrade, and then were stopped by 
the addition of SN hydrochloric acid at one minute intervals. 
Absorbance was then measured for each sample in a Beckman 
spectro-colorimeter Model 151 (41). 
Calculation of Blood Glucose 
Blood sugar levels can be determined by multiplying by 
100, the ratio of the absorbance reading recorded on the Beckman 
spectro-colorimeter, for the unknown sample, and for the glucose 
standard (41). 
unknown 
X 100 = mg glucose/100 ml. 
standard 
CHAPTER V 
EXPERIMENTS AND RESULTS 
Experiment No. 1 - Yeast Hexokinase 
Dependability of the DiPietro and Weinhouse assay 
system and of the reagents was assured by the employment of Sigma 
grade, type III, yeast hexokinase, activity 8 to 12 units/mg., in 
early experimental procedures. 
Sample preparation was accomplished by dissolving 1 mg. 
of enzyme per ml. of 0.15 molar Tris-HCl buffer pH 7.5. 
Quantities ranging between 0.1 ml. and 1.0 ml. were added 
directly to the assay system, and the formation of NADPH was then 
followed spectrophotometrically at 340 nanometers with the 
Beckman D.U. spectrophotometer, or the Calbiochem Calbiometer. 
Experimental procedures consisted of recording the 
optical density for a ten minute period at 25 ± 1 degrees 
centigrade after the sample had been added to the assay system. 
All readings were corrected for a low optical density by sub-
tracting the optical density measured with all reagents except 
ATP. 
Glucose concentration of the assay system was altered 
to 0.00375 to allow measurement of hexokinase activity only. 
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calculations 
Since experimentation was ~arried out employing samples 
of .0.1 ml. and 1.0 ml., each three times, optical density could 
be calculated statistically: 
~O.D./10 min. = 60.D./min. 
a 60.D. of 4.14 = one unit of hexokinase activity 
60.D./min./4.14 = units of hexokinase activity 
Sum of 60.D./min./3 = average 60.D./min. 
,· Sum (60.D.) 2 - (Sum 60.D.) (Sum 60.D. 2) 
Number of Experiments 1 Variance = 
Standard Deviation = Square root of the variance 
Results 
TABLE V 
ENZYMATIC ACTIVITY OF YEAST HEXOKINASE 
Hexokinase Activity Hexokinase Activity 
Experiment (O .1 ml. Sample) (1.0 ml. Sample) 
No. (uni ts/mg.) (uni ts/mg.) 
1 1.83 10.2 
2 1.76 9.80 
3 1.81 9.69 
TABLE VI 
MEAN ENZYMATIC ACTIVITY OF YEAST MEXOKINASE 
Mean Hexokinase 
Activity· ± · s . D. ··· 
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. \ 
Volume 
Employed (uni ts/mg.) Variance Standard Deviation 
O.l ml •. 1. 80 ± 6. H> 
1.0 ml. 9.89 ± 0.80 
.01 
.69 
0.10 
0.80 
Experiment No. 2 - Normal and Diabetic Animal Hexokinases 
Holtzman male rats weighing between 200 and 300 grams 
were fed on a normal diet, and prior to decapitation, were 
injected with 0.09 molar saline solution. After decapitation, 
their livers were removed and weighed. One gram samples were 
homogenized in two volumes of homogenizing buffer and centrifuged 
for 80 minutes at 100,000 x g. Following centrifugation, the 
supernatant was passed directly through a column of G-25 Sephadex 
and fractions were collected. Hexokinase and glucokinase activi-
ty' of the sample was then measured by the method described 
previously. 
Experimental procedure consisted of selecting eight 
normal male rats, numbering and weighing them, and injecting them 
with 1 ml./kg._ of animal weight of saline. Such procedure was 
followed because the oral hypoglycemic agents used were prepared 
in saline solution (See Appendix Table XXVII) • 
; ... 
f. 
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HEXOKINASE AND GLUCOKINASE ACTIVITY OF CONTROL ANIMALS 
Animal No 
1 
2 
3 
4 
5 
6 
7 
8 
Number of 
Animals 
8 
.. 
· Hexokinase Activity · 
(units/gram liver) 
·Glucokinase Activity 
(unitslgram liver) 
.351 .710 
.381 .645 
.366 .670 
.320 .771 
.790 .902 
.371 .806 
.434 .889 
.410 .692 
TABLE VIII 
MEAN HEXOKINASE AND GLUCOKINASE 
ACTIVITY OF CONTROL ANIMALS 
Mean Hexokinase 
Activity:!:: S.D. 
.427 + .13 
Glucokinase 
Activity±: S.D. 
.754 + .20 
Variance 
.170 
.042 
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Diabetic Animal Hexokinases 
_ ~r~paration of .. the .. diabetic s.tate was accomplished by 
the administration of 60 mg./kg. of animal-weight of alloxan 
following a period of 24 hour fasting. Hyperglycemia was found 
to exist 72 hours after treatment. 
Assurance that the animals were sufficiently diabetic 
was demonstrated by measuring the glucose levels of blood samples 
collected from the tail vein of each alloxan-treated animal. 
Levels of 200 mg. per cent and over were considered to be 
sufficient for experimental use. 
Upon completion of the preparation of the diabetic 
state, the animals were decapitated, and their livers were 
removed, weighed, and homogenized. Samples were then carefully 
applied to the previously described assay system. 
Since the mechanism of action of alloxan can be 
explained as being due to a destruction of the B-cells of the 
pancreas, thereby limiting or completely stopping the release of 
endogenous insulin, many of the treated animals entered into 
severe diabetic coma and expired (See Appendix Table XXVIII) • 
Hexokinase and glucokinase activities were measured, 
calculated, and recorded in Table IX. 
'· 
; 
" 
. TABLE IX 
HEXOKINASE AND GLUCOKINASE ACTIVITY OF 
DIABETIC.ANIMALS 
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Animal No. Hexokinase Activity Glucokinase Activity 
and its (units/gram liver) (units/gram liver) 
Diabetic State 
1 231 mg3 .231 .083 
2 321 .205 .108 
3 209 .248 .093 
4 629 .315 .101 
5 303 .198 .078 
6 201 .221 .081 
7 250 .351 .099 
8 289 .253 .091 
TABLE X 
MEAN HEXOKINASE AND GLUCOKINASE ACTIVITY OF 
DIABETIC ANIMALS 
Number of 
Animals 
8 
Mean Hexokinase 
A • • S n ctivity + .~. 
(units/gram liver) 
.250 + .06 
Glucokinase 
Activity+ S.D. 
(units/gram liver) 
.092 + .028 
Variance 
.004 
.008 
Experiment No. 3 - The Effect of In Vivo Administration 
of Phenf ormin on Hexokinases 
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Male Holtzman rats were allowed access to regular rat 
chow until needed. Following administration of the drug, 
phenformin, they were decapitated and their livers removed. One 
gram samples were homogenized, centrifuged, and passed directly 
through a column of G-25 Sephadex prior to utilization in the 
afore mentioned assay system. 
Administration of the drug was accomplished by inter-
peri toneal injection of 0.10 rnMoles/150 grams of animal weight. 
Since all of the drugs used in experimental procedures were 
prepared in saline solution, control animals were treated with 
an equal dose of saline. One group of male rats was treated with 
0.3 units/ml. of bovine insulin in order to establish some 
comparison between the effects of insulin and of the oral hypo-
glycemic agent on the enzyme system. 
Experimental methods consisted of those used in 
previous experiments. Animals were numbered, weighed, and 
separated into different groups prior to treatment (See Appendix 
Table XXIX). 
Upon completion of the procedures shown in Table XXIX, 
the hexokinase and glucokinase activity for each animal was 
measured and recorded (See Table XI and Table XII) . 
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TABLE XI 
... HEXOKINASE AND GLUCOK.INASE AC'l'IVI'l'IES OF 
NORMAL ANIMALS TREATED WITH SALINE~ PHENFORMIN, AND INSULIN. 
Hexokinase Activity Glucokinase Activity 
Animal. No. (units/gram li,ver} (units/gram liver} 
1 .392 .781 
2 .441 1.01 
3 .301 .744 
4 .349 .521 
5 .458 .690 
6 .409 .713 
7 .340 1.08 
8 .310 .641 
9 .501 1.02 
10 .340 .881 
11 .420 .741 
12 .366 .736 
13 .385 .545 
14 .521 .789 
15 .259 .642 
16 .491 .921 
17 .328 .726 
18 .247 .643 
19 .411 .828 
.. 
' 20 .362 .709 
,, 
.. 
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TABLE XII 
MEAN HEXOKINASE. AND. GLUCOKINASE ACTIVITY 
Mean iiexokinase Mean Glucokinase 
Activity ± S.D. Activity ± s.o. 
Animal No. (units/gram liver) (units/gram liver) variance 
1 - 4 .371 ± .• 10 .010 
.823 ± .17 .016 
5 - 8 .380 ± .06 .003 
.780 ± .12 .026 
9 - 12 .407 ± .02 .005 
.742 ± .18 .03 
13 - 16 .409 ± .18 .03 
.723 ± .16 .025 
;> 
17 - 20 .352 ± .07 .005 
.726 ± .24 .050 
!?Cperiment No. 4 - The Effect of Phenformin In Vivo on 
Hexokinases of Diabetic Animals , 
. . . 
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Male.Holtzman rats were made diabetic through .the 
procedure described previously." They were then injected with 
either .09 molar saline or phenformin and decapitated at 
different intervals after treatment. One group of diabetic rats 
was treated with insulin in order to establish a comparison 
between the oral hypoglycemic agent and insulin (See Appendix 
Table XXX). 
Hexokinase and glucokinase activities were measured and 
recorded in Tables XIII and XIV. 
TABLE XIII 
HEXOKINASE AND GLUCOKINASE ACTIVITIES OF ANIMALS 
Animal No. 
1 
2 
3 
4 
5 
6 
7 
8 
IN THE DIABETIC STATE TREATED WITH 
SALINE, PHENFORMIN, AND INSULIN 
Hexokinase Activity 
(units/gram liver) 
.361 
.452 
.287 
.395 
.219 
.356 
.186 
.381 
Glucokinase Activity 
(units/gram liver) 
.923 
1.02 
.781 
.691 
.180 
.097 
.125 
.083 
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9 .421 .106 
10 .208 .063 
11 .326 .099 
12 .358 .112 
\ 
13 .098 .042 
- 14 .397 .118 
15 .343 .092 
16 .412 .078 
17 .512 .140 
18 .346 .088 
19 .188 .094 
20 .319 .124 
21 .409 .515 
22 .425 .846 
23 .382 1.12 
24 .321 .731 
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TABLE XIV 
MEAN HEXOKINASE AND GLUCOKlNAS.E ACTIVITIES 
Mean Hexokinase Mean Glucokinase 
Activity ± S.D. Activity ± S.D. 
Animal No. (units/gram liver) (units/gram liver) Variance 
1 - 4 .373 ± .13 .02 
.846 ± .14 .03 
5 - 8 .285 ± .16 .015 
• .121 ± .08 .008 
9 - 12 .328 ± .27 .08 
.095 ± .03 .001 
13 - 16 .312 ± .10 .010 
.082 ± .01 .0003 
17 
-
20 .341 ± .17 .016 
.111 ± .05 .003 
21 - 24 .384 ± .10 .010 
.806 ± .16 .030 
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TABLE XV 
HEXOKINASE AND GLUCOKINASE ACTIVITIES OF. 
NORMAL ANIMALS TREATED WITH SALINE,. PHENFORMIN, AND INSULIN 
This series of experiments was carefully repeated and 
the results obtained were recorded below (See Appendix Table XXXI 
l· 
for animal preparation) . 
Hexokinase Activity Glucokinase Activity 
Animal No. (units/gram liver) (units/gram liver) 
1 .199 .747 
2 .599 .631 
3 .456 .821 
4 .483 .754 
5 .376 1.01 
6 .561 .544 
7 .312 .881 
8 .421 .876 
9 .321 .592 
10 .325 .649 
11 .283 .739 
12 .345 .701 
13 .418 .645 
14 .381 .715 
15 .195 .473 
16 .397 .541 
17 .418 .488 
18 .542 .784 
19 .398 .990 
20 .498 .776 
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TABLE XVI 
. ME}.N HEXOKINASE AND GLUCOKINASE . ACTIVITY . 
Mean Hexokinase Mean Glucokinase 
Activity ± S.D. Activity ± S.D. 
Animal No. (units/gram liver) (units/gram liver) Variance 
1 - 4 .424 ± .24 .06 
.738 ± .20 .04 
5 - 8 .417 ± .10 .01 
t .821 ± .24 .06 
~ 9 - 12 .321 ± .10 .01 ~ ,.. 
" 
.690 .22 .05 r'~- ± 
-
' ~ ... ~~ > 13 16 .350 ± .16 .025 L -
.. 
.643 '± .17 .03 
l« 
17 - 20 .411 ± .20 .04 
.802 ± .20 .04 
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TABLE XVII 
HEXOKINASE AND GLUCOKINASE ACTIVITY OF 
DIABETIC ANIMALS TREATED WITH SALINE, PHENFORMIN, AND INSULIN 
This series of experiments was carefully repeated and 
'. the results obtained were recorded below (See Appendix Table 
J; XXXII for animal preparation). ~· 
;-
f Diabetic Hexokinase Glucokinase 
F state Activity Activity 
'• Animal No. Cm2%) (units/2ram liver) (units/gram liver) 
" -~· l .193 .514 
2 .312 .498 
3 .317 .631 
4 .301 .678 
5· 230 .241 .045 
6 210 .237 .073 
7 344 .198 .062 
a 276 .178 .242 
9 403 .311 .067 
10 329 .341 .061 
11 207 .298 .109 
12 200 .261 .054 
13 314 .265 .087 
14 289 .293 .079 
15 253 .241 .035 
16 236 .306 .069 
17 200 .217 .103 
18 301 .316 .081 
19 413 .198 .051 
20 219 .257 .059 
f:.~, 
21 
22 
23 
24 
Animal No. 
1 - 4 
5 - 8 
9 - 12 
13 - 16 
17 - 20 
21 - 24 
~ 
210 .312 .734 
265 .261 .511 
342 .341 .640 
379 .218 .454 
TABLE XVIII 
MEAN HEXOKINASE AND GLUCOKINASE ACTIVITY 
Mean Hexokinase 
Activity ± S.D. 
(units/gram liver) 
.280 ± .07 
.213 ± .14 
.302 ± .17 
.301 ± .22 
.246 ± .07 
• 281 ± ·.14 
Mean Glucokinase 
Activity ± S.D. 
(units/gram liver) 
.580 ± .07 
.105 ± .10 
.072 ± .10 
.067 ± .01 
.073 ± .15 
.592 ± .16 
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\ . 
Variance 
.006 
.006 
.020 
.012 
.030 
.020 
.050 
.003 
.006 
.002 
.020 
.050 
Experiment No. 5 - The Effects of the In Vivo 
Administr~tion of Tolbutamide on the Hexokinases of 
Normal and Diabetic Animals 
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This series of experiments was conducted in order to 
establish the effect of tolbutamide on the hexokinases and to 
establish a comparison between its effect and the effect caused 
by insulin. 
Experimental procedures consisted of injecting male 
Holtzman rats with 0.35 InMoles/150 grams of animal weight of 
tolbutamide. These were then decapitated at different intervals 
after injection; their livers were removed; and one gram samples 
were carefully homogenized and used in the assay system described 
in previous experiments (See Appendix Table XXXIII) • 
Experimental results are recorded in Tables XIX and 
xx. 
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TABLE XIX 
HEXOKINASE AND.GLUCOKINASE ACTIVITIES OF 
NORMAL ANIMALS TREATED WITH SALINE, TOLBUTAMIDE, AND INSULIN 
Hexokinase Activity Glucokinase Activity 
Animal No. (un.i ts/gram· liver) {units/2rarn_ liver) 
1 .141 .384 
2 .163 .511 
3 .299 .458 
4 .211 .349 [ 
' 
5 .284 .478 
l 6 .245 .602 7 .178 .491 8 .398 .536 
[: 9 .288 .429 
t 10 .275 .473 t· 
f 11 .199 .510 1, 12 .219 .388 
13 .198 .321 
14 .228 .369 
15 .250 .442 
16 .273 .481 
17 .251 .521 
18 .309 .452 
19 .308 .429 
20 .362 .544 
l....___ ____ ____. 
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TABLE XX 
MEAN HEXOKINASE AND GLUCOKINASE ACTIVITY 
Mean Hexokinas·e M~an Glucokinase 
Activity ± s.o. Activity ± s.o. 
Animal No. ·(uni ts/gram liver) (units/gram liver) Variance 
1 - 4 .278 ± .10 .01 
.425 ± .03 .001 
5 - 8 .276 ± .07 .006 
.521 ± .03 .001 
9 - 12 .263 ± .09 .008 
.450 ± .05 .003 
13 - 16 .272 ± .06 .004 
.413 ± .07 .005 
17 - 20 .306 ± .08 .008 
.486 ± .17 .016 
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TABLE XXI 
.HEXOKI.NASE AND GLUCOKINASE ACTIVITIES OF DIABETIC 
ANIMALS TREATED WITH SALINE AND TOLBUTAMIDE 
(See Appendix Table XXXIV for animal preparation) 
Diabetic Hexokinase Glucokinase 
State Activity Activity 
Animal No. (mg%) (units/gram liver) (units/gram liver) 
1 .274 .445 
2 .153 .368 
3 .205 .398 
4 .238 .379 
5 230 .186 .048 
6 200 .208 .035 
7 308 .175 .064 
8 265 .351 .045 
9 434 .234 .442 
10 256 .315 .412 
11 308 .161 .328 
12 318 .241 .196 
13 200 .228 .198 
14 299 .309 .357 
15 345 .186 .384 
16 270 .241 .366 
17 201 .091 .041 
18 340 .324 .631 
19 205 .309 .422 
20 275 .279 .399 
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TABLE XXII 
MEAN HEXOKINASE AND GLUCOKINASE ACTIVITY 
i . •. 
Mean Hexokinase Mean Glucokinase 
Activity ± S.D. Activity ± S.D. 
Animal No • (units/9:ram liver) (units/gram liver) Variance 
.. . 
F 1 - 4 .237 ± .02 .004 ~.·' ,  
F 
' 
.397 .006 l ± .02 \ 
~; 
f· 5 - 8 .230 ± .12 .016 
.048 ± .01 .002 
9 - 12 .237 ± .017 .003 
.345 ± .15 .026 
13 - 16 .216 ± .11 .013 
.325 ± .01 .003 
17 
-
20 .249 ± .01 .001 
.373 ± .27 .050 
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TABLE XXIII 
HEXOKINASE AND GLUCOKINASE ACTIVITIES OF 
·· .. 
NORMAL ANI~LS .TREATED WITH SALINE, TOLBUTAMIDE, AND INSULIN 
This series· of experiments was carefully ··repeated arid 
the results -obtained were recorded below (See Appendix Table XXXV 
for animal preparation). 
Hexokinase Activity Glucokinase Activity 
Animal No. (units/9ram liver) (units/gram liver) 
l .356 .987 
2 .481 .641 
3 .423 .596 
4 .279 .721 
5 .479 .838 
6 .321 .641 
7 .350 .720 
8 .511 .678 
9 .391 .811 
10 .426 .801 
11 .309 .781 
12 .299 .701 
13 .302 .678 
14 .472 .749 
15 .321 .981 
16 .301 .713 
17 - .421 .790 
18 .399 .711 
19 .389 .894 
20 .441 .731 
68 
TABLE XXIV 
MEAN -HEXOKINASE AND GLUCOKINASE ACTIVITY . 
Mean Hexokinase Mean Glucokinase 
., . 
·Activity ± S.D. Activity ± S.D. 
Animal No. (uni ts/Gram liver) (.uni ts/gram liver) Variance 
1 - 4 .384 ± .26 .070 
.736 ± .21 .040 
5 - 8 .415 ± .14 .021 
.719 ± .24 .060 
i 9 - 12 .356 ± .17 .030 
! .771 ± .12 .016 r 
' 
' !' 13 16 .349 ± .20 .040 -
.779 ± .16 .026 
17 - 20 .412 ± .12 .015 
.756 ± .17 .030 
TABLE XXV 
HEXOKINASE AND GLUCOI<INASE.ACTIVITIES OF DIABETI:C 
ANIMALS TREATED WITH SALINE, TOLBUTAMIDE AND 
INSULIN 
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This.series of experiments was carefully repeated and 
the results obtained were recorded below (See Appendix Table 
XXXVI for animal preparation. 
Diabetic Hexokinase Glucokinase 
State Activity Activity 
. Animal No. (ms;r%) (units/s;rram liver) (units/gram liver) 
l .341 .721 
2 .298 .642 
3 .421 .731 
4 .367 .768 
5 239 .212 .087 
6 341 .188 .045 
7 217 .349 .093 
8 447 .357 .129 
9 209 .109 .097 
10 315 .231 .242 
11 427 .342 .285 
12 304 .285 .512 
13 251 .249 .548 
14 270 .571 .621 
15 245 .339 .609 
16 372 .168 .735 
17 419 .389 .431 
70 
18 319 .251 .742 
19 200 .218 .435 
20 257 .• 347 .• 849 
.. 
21, 378 .381 .773 
22 212 .234 .741 
23 ·503 ·_-353 . .691 
24 209 .321 .764 
TABLE XXVI 
MEAN HEXOKINASE AND GLUCOKINASE ACTIVITY 
Mean Hexokinase Mean Glucokinase 
Activity ± S.D. Activity ± S.D. 
Animal No. (units/gram liver) (units/gram liver) Variance 
1 - 4 .356 ± .20 .050 
.738 ± .20 .040 
5 - 8 .275 ± .10 .020 
.088 ± .02 .004 
9 - 12 .241 ± .12 .015 
.284 ± .01 .001 
13 - 16 .331 ± .16 .034 
.618 ± .10 .020 
17 
- 20 .301 ± ~04 .002 
.664 ± .01 .001 
21 - 24. .347 ± .02 .004 
.726 ± .22 .050 
CHAPTER VI 
DISCUSSION AND CONCLUSION 
Statistical evaluation of the experimental results 
found in the preceding chapter substantiates certain conclusions. 
The first series of experiments involved the use of 
yeast hexokinase in experimental procedures, the purpose of this 
being to ascertain the dependability of the assay system and of 
the reagents. Since Sigma yeast hexokinase has an activity of 
8 to 12 units per milligram, it could serve as an adequate 
standard. Results obtained from the incorporation of 1.0 and 
0.1 ml. samples in the assay system indicated sufficient accuracy 
' relative to the previously determined value. 
After determination of the dependability and the 
adaptability of the assay system, this technique was utilized to 
measure hexokinases and glucokinases of both normal and diabetic 
animals. Experimental results have substantiated the work of 
Sharma (70) and of venuela, Salas, and Sols (61, 78), in that the 
glucokinase activity was approximately two to three times greater 
than hexokinase in normal animals, and conversely, hexokinase was 
found "to be 2·to 3 times greater than glucokinase in diabetics 
(See Figures 5 and 6). 
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Further experimentation followed similar procedures, 
but differed in that it measured hexokinase.and glucokinase 
. . 
activity of normal animals treated with saline, normal animals 
treated with phenformin arid decapitated at different intervals 
after treatment, and normal animals treated with insulin. The 
results indicated that there was no measurable increase or 
decrease in hexokinase or glucokinase activity after the adminis-
tration of phenformin (See Figures 7, 8, 9 and 10). 
An explanation of these results follows logically from 
what is known about the mechanism of action of phenformin. Its 
hypoglycemic effect can be attributed to several factors; 
namely: (a) there is an enhancement of the action of insulin 
that is available in the cells and which was previously unre-
sponsive, (b) there is a decrease in muscle glycogen and a marked 
increase in lactic acid production, and (c) there appears to be 
a stimulation of the oxidative utilization of glucose (56, 98) 
The hexokinase isozymes have previously been described 
as catalyzing the reaction 
hexokinase 
glucose + ATP glucose-6-phosphate + ADP 
which does not lend itself to any phase of the mechanism of 
phenformin. Consequently, there is no good reason to expect that 
an increase or a decrease in hexokinase or glucokinase activity 
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would be found in liver cells. 
Subsequent experimentation expanded the previously 
. .
described techniques and adapted them to animals that had been 
t f treated with tolbutamide. Evaluation of the results indicated 
~ 
!·· 
that there had been an increase in hex-kinase and glucokinase 
activity in both the diabetic and normal animal. A marked 
increase of glucokinase activity was observed in the diabetic 
animal, whereas there was only a slight increase in the activity 
of the normal animal. The increase in hexokinase activity that 
was measured in the normal animal was very minor and is of such 
a level that it can be· explained simply as falling within the 
range of experimental error (See Figures 11, 12, 13 and 14). 
In the tolbutamide experiments, the increase in 
glucokinase activity of liver tissue in both diabetic and normal 
animals can be attributed to the mode of action of tolbutamide, 
whose hypoglycemic effect can be explained as a stimulation of 
the beta-cells of the pancreas to secrete or release excess 
endogenous insulin, an increase in the utilization of readily 
pre-existing insulin, or an increase in the formation of new . 
beta-cells, a process known as beta-cytotrophic action (20, 98). 
Work by Venuela, Salas, and Sols has shown that gluco-
kinase is an insulin-dependent enzyme. Therefore, as insulin is 
increased, glucokinase activity is increased (61, 78). Their 
work, which was related to the biosynthesis of liver glucokinase, 
.60 0 
.50 
a:: 
··w 
>.40 
-
_J 
0 
0 
::? 
<( .300 
a:: 
(!) 
,. 
CJ) .20 
~ 
-z 
0 
::> .10 0 
.o 10( 
a-
.. 
--
A 
6 
HEXOKINASE ACTIVITY OF 
-.-
--
8 
N ORMAL ANIMALS 
.... 
... 
·-
E 
HOURS 
FIGURE 11 
. 
a-
.. , 
, a-
.... 
c D 
12 24 
A= NORHAL ANIMALS T:1E.ll. TSD 
WITH SALINS 
B,C,D,= TREATED WITH 
TOLBUTAMIDE 
E= TREATED WITH INSULIN 
I 
I 
I 
i 
;• 
i 
~-
" 
,. 
\ 
a:: 
w 
.900 
> 
:J-800 
~ 
<t 
a::.700 
. (.!) 
' ~.600 
-z 
:::> 
. 500 
.400 
.... 
. ... 
A 
GLUCOKINASE AGTIVITY . OF 
6 
NORM AL ANIMALS 
·-
·-
, . 
. 
...... 
.... 
·s E 
HOURS 
FIGURE 12 
--
-
_ .... 
c D 
12 24 
A= NORMAL ANIMALS TR~ATED 
WI'l'H SALINE 
B,C,D,= TREATED WITH 
'i~OLBU'I1AMIDE 
E= TREATED vJI'I'E INSULIN 
.500 
a:: 
w 
>-
--400 
__. 
~ 
<C.300 
a:: 
<.!> 
(1)-200 
t-
-z 
:::> 
. 100 
.ooo 
--
_._ 
A 
HEXOKINASE ACTIVITY OF · 
·-
_..__ 
8 
6 
. 
DIABETI C ANIMALS 
• f. 
--
-.... 
c 
HOURS 
FIGURE 13 
--
I 
·-
-.. 
-
... 
. ... 
F D E 
12 24 
A= NORMAL ANIMALS TREATED 
WITH SALINE 
B= DIABETICS l:f Pl'H SALINE 
C,D,E,= DIABETICS WITH 
TOLBIJ'fAMIDE 
f~ DIABETICS WITH INSULIN 
0:: 
w 
> 
·800 
.700 
::J .600 
~ 
<( 
a:: .300 
(.!) 
' ~-200 
·-z 
:::> 
.100 
.ooo 
--
--
..... 
A B 
6 
GLUCOKIN ASE ACTIVITY OF 
DIABET IC ANIMALS 
' .  
T 
-L 
c 
HOURS 
FIGURE 14 
. 
·-
·-
·-
F D E 
12 24 
A= NORMAL ANIMALS TRSATED 
WITH SALINE 
B= DIABETICS WITH SALINE 
C,D,E,= DIABETICS WITH 
TOLSU'i'AMI DE 
F= DIABETICS WITH INSULIN 
74 
also postulates that glucokinase disappears in vivo under 
---
conditions of fasting and alloxan di~etes. 
Since the mechanism of action of alloxan can be 
explained as being due to a destruction of the beta-cells of the 
pancreas, thereby causing a cessation of the release of endo-
genous insulin, and since glucokinase has already been 
established as an insulin-dependent enzyme, the conclusions of 
Venuela, Salas, and Sols are well founded. Consequently, the 
release of excess insulin through the action of tolbutamide can 
account for the increase in glucokinase activity in both the 
diabetic and normal animal. Although it would appear reasonable 
that there should be no effect on the glucokinase activity. of the 
diabetic, since previous researchers have stipulated that this 
enzyme disappears, it seems possible from the measurement of 
glucokinase activity in these animals after treatment with 
tolbutamide, that some of the activity does remain. This 
remaining activity indicates that not all of the beta-cells were 
destroyed, or that the tolbutamide has caused beta cytotrophic 
action to take place, producing more cells that liberate insulin 
and thereby increasing glucokinase activity (See Figures 13 and 
14) • 
The resu·l ts recorded · in the preced~ng chapter -have 
indicated that there is no effect on the hexokinase or gluco-
75 
kinase activity of diabetic and normal animals after treatment 
. . 
with,phenformin, but that there is an increase in glucokinase 
- . . 
activity of both after interperitoneal administration of tolbu-
tamide. Insulin administiat.:j_on brought°. glucokinase activi-ty back 
to normal in the diabetic and to slightly higher than normal 
levels in the control animals. Saline injections were found to 
have no effect on the hexokinase system. This work also sub-
stantiates the work of Sharma, Manjeshwar, and Weinhouse (70), 
who studied the normonal regulation of hepatic glucokinase (32, 
37). 
Treatment of some of the animals with insulin, followed 
by a study of the in vivo effect on the hexokinase and gluco-
kinase activity, was employed for the purpose of confirming work 
previously accomplished. It also served as a control for the 
experimental procedure, in order to establish some correlation 
between the action of insulin and of the hypoglycemic agents. 
r 
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TABLE XXVII 76 
THE PREPARATION AND TREATMENT OF NORMAL ANIMALS 
,. 
Male Holtzman rats weighing between 200 and 350 grams 
. ' 
e.re weighed, treated with saline and decapitated. Their livers 
ere removed, weighed, and homogenized. 
Animal No. Animal Weight Liver Weight Treatment 
(in grams) (in grams) (ml. saline) 
1 220 9.2 .22 
2 250 8.9 .25 
3 245 9.1 .24 
4 260 10.4 .26 
5 310 12.1 .31 
6 380 10.9 .38 
7 230 9.4 .23 
8 350 10.2 .21 
r 
' 
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TABLE XXVIII 
THE PREP~RATION AND TREATMENT .OF.DIABETIC ANIMALS 
.. 
Male Ho_ltzman rats w~i~hing between 200 and 350 grams ·' 
· were·· weighed, ·treated with· alloxan, · and decapitated. Their livers· 
!Vlere removed·, we,ighed and homogenized. 
Animal No. 
l 
2 
3 
4 
5 
6 
7 
8 
Animal Weight 
{in grams) 
330 
380 
410 
300 
250 
351 
350 
310 
Liver Weight 
· (in grams) 
8.6 
10.9 
12.0 
8.3 
7.9 
11.9 
9.2 
8.9 
Treatment 
(ml. alloxar 
.33 
.38 
.41 
.30 
.25 
.35 
.35 
.31 
TABLE XXIX 78 
THE PREPARATION AND TREATMENT OF NORMAL ANIMALS 
WITH PHENFORMIN 
Male-Holtzman rats weighing between 200- and 350 grams 
ere weighed, . t~eated with . saline, phenformin, and insuli_n, 
and were decapitated at different intervals after treatment. Their 
livers were removed, weighed, and homogenized. 
Animal No. Animal Weig_ht Liver Weight Treatment 
(in grams) (in grams) (ml. saline) 
l 210 8.1 .21 
2 240 9.3 .24 
3 225 8.5 .22 
4 270 10.5 .27 
Deca:eitated 6 hours after treatment Phenf ormin 
5 300 10.3 .76 
6 220 7.9 .60 
7 250 8.9 .68 
8 310 9.2 .77 
Deca:eitated 12 hours after treatment Phenf ormin 
9 360 10.2 .89 
. 10 300 9.1 • 75 .. 
11 280 7.8 .70 
12 300 9.7 .76 
r 
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Decapitated after 24 hours after treatment Phenf ormin 
13 290 8.8 .74 
14 220 7;9 .60 
15 256 8.~ ' .6Q 
16 300 - 11.2 .. • 76. 
DecaEitated 12 hours after treatment Insulin 
17 325 8.3 1.0 
18 340 8.7 1.0 
19 383 9.5 1.0 
20 350 9.8 1.0 
TABLE XXX 80 
THE PREPARATION AND TREATMENT OF DIABETIC 
ANIMALS WITH PHENFORMIN 
Male Holtzman rats weighing between 200 and 350 grams 
weighed, treated with alloxan, and inj.ected with saline, 
henformin, and insulin. These animals were then decapit~ted and 
eir livers were removed and homogenized. 
Animal No. Animal Weight Liver Weight Treatment 
(in grams) ·(in 9rarns) ·cm1. saline) 
1 300 8.2 .30 
2 329 9.1 .32 
3 315 7.6 .31 
4 387 10.4 .38 
Diabetic animals treated with saline Saline 
5 291 6.9 .29 
6 302 9.1 .30 
7 335 9.4 .33 
8 350 11.0 .35 
Diabetic animals treated with phenformin 
deca;eitated 6 hours after treatment Phenf orrnin 
9 280 8.9 .71 
10 259 7.6 .65 
11 298 8.2 • 75 
12 301 9.7 .76 
r 
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Decapitated 12 hours after treatment Phenf ormin 
13 275 7.8 .69 
,, 
14 309 9.8 .78 
15 325 10-.2 .82 
16 290 8.6 .73 
Decapitated 24 hours after treatment Phenf ormin 
17 269 8.1 .68 
18 250 7.2 .62 
19 312 9.0 .78 
20 294 8.5 .73 
Decapitated 12 hours after treatment Insulin 
21 210 9.1 1.0 
22 259 8.2 1.0 
23 321 10.8 1.0 
24 278 7.8 1.0 
TABLE XXXI 82 
THE PREPARATION AND TREATMENT OF NORMAL ANIMALS 
WITH-PHENFORMIN 
Animal -No. Animal Weight _Liver Weight Treatment 
(in grams) (in grams) ( ml Saline) 
1 312 9.0 .31 
2 400 11.5 .40 
3 337 8.1 .33 
4 350 9.1 .35 
Decapitated 6 hours after treatment · Phenfromin 
5 325 8.4 .82 
6 330 8.7 .83 
7 319 9.1 .80 
8 329 9.4 .83 
Decapitated 12 hours after treatment Phenf ormin 
9 380 10.6 .96 
10 351 9.8 .88 
11 338 11.1 .85 
12 309 8.9 .78 
Deca12itated 24 hours after treatment Phenf ormin 
13 310 8.4 .79 
14 319 9.1 .80 
15 335 8.5 .84 
16 298 7.4 .75 
r 
TABLE XXXII 83 
THE PREPARATION AND TREATMENT OF DIABETIC ANIMALS 
WITH PHENFORMIN 
Animal No. 
1 
2 
3 
4 
Anima-1 Weight 
(in grams) 
310 
287 
309 
278 
Liver Weight 
(in grams) 
8.1 
7.5 
8.3 
7.7 
Diabetic animals treated with saline 
5 
6 
7 
8 
311 
298 
308 
315 
9.0 
8.2 
8.3 
8.7 
Diabetic animals treated with phenformin 
and decapitated after 6 hours 
9 
10 
11 
12 
291 
345 
319 
321 
7.8 
10.1 
9.2 
8.5 
Decapitated 12 hours after treatment 
13 
14 
15 
16 
275 
267 
341 
329 
7.4 
8.0 
8.6 
8.4 
Treatment 
(ml saline) 
.31 
.28 
.30 
.27 
Saline 
.31 
.29 
.30 
.31 
Phenf ormin 
.74 
.87 
.71 
.72 
Phenf ormin 
.69 
.68 
.86 
.82 
r 
I ( 
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Decapitated 24 hours after treatment Phenf ormin 
17 313 8.5 .78 
18 306 8.0 .77 
19 331 9.6 ;94 
20 297 . 7.. 9 .74 
Decapitated 12 hours after treatment Insulin 
21 351 10.4 1. o. 
22 256 8.1 1.0 
23 303 8.5 1.0 
24 301 8.0 1.0 
85 
TABLE XXXIII 
THE PREPARATION AND TREATMENT OF NORMAL ANIMALS 
WITH TOLBUTAMIDE 
Male Holtzman rats weighing between 200 and 350 grams 
ere weighed, treated with saline, tolbutamide, and insulin, 
nd were· decapitated at different intervals after treatment. Their 
ivers were removed, weighed, and homogenized. 
Animal No. Animal Weight Liver Weight Treatment 
(in grams) (in: grams)· (ml saline) 
1 335 8.6 .33 
2 321 8.3 .32 
3 380 . 9. 4 .38 
4 365 10.4 .36 
Decapitated 6 hours after treatment Tolbutamide 
5 290 7.6 .30 
6 300 7.9 .31 
7 310 8.2 .32 
8 327 8.5 .33 
Deca,eitated 12 hours after treatment · · Tolbutamide 
9 341 9.1 .35 
10 323 9.2 .33 
11 275 7.6 .28 
12 280 8.1 .29 
r 
r 
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Deca:12itated 24 hours after treatment Tolbutamide 
13 315 8.5 .32 
14 370 •' 9. 6 .38 
15 350 8.9 .36 
16 351' 8.8 .36 
Deca:12itated. 12 hours after treatment Insulin 
17 305 8.4 1.0 
18 350 9.5 1.0 
19 331 10.0 1.0 
20 325 8.7 1.0 
87 
TABLE XXXIV 
THE PREPARATION AND TREATMENT OF DIABETIC ANIMALS 
WITH TOLBUTAMIDE 
Male Holtzman rats weighing· 'between 200 and 350 grams 
ere weighed, treated with alloxan, and injected with saline, 
tolbutamide, and insulin. These animals were then decapitated 
at different intervals after treatment and their livers were re-
oved and homogenized. 
Animal No. 
1 
2 
3 
4 
Animal Weight 
(in grams) 
361 
330 
275 
304 
Liver Weight 
·('in grams) 
10.2 
9.0 
7.8 
8.2 
Diabetic animals treated with saline 
5 
6 
7 
8 
350 
348 
342 
354 
9.7 
8.9 
8.5 
9.5 
Diabetic animal treated with tolbutamide 
decapitated 6 hours after treatment 
.9 
10 
11 
326 
340 
337 
8.5 
9.1 
7.6 
Treatment 
(ml saline) 
.36 
.33 
.27 
.30 
Saline 
.35 
~34 
.34 
.35 
Tolbutamide 
.33 
.35 
.34 
88 
12 313 8.4 .32 
Decapitated 12 hours after treatment Tolbutarnide 
' . 
... 
.13. 350 . 9. 9 .36 ,. 
14 340 9.4 .35 
.. ·~ - . 
15 324 8.7 .33 
... 
:· 
16 . 344 8.8 .35 
;· .. ,. 
Decapitated 24 ·hours after · treatrne·nt Tolbutarnide 
17 402 11.4 .41 
18 360 10.l .37 
19 348 9.8 .35 
20 335 9.5 .34 
r 
89 
TABLE XXXV 
THE P~PARATION AND TREATMENT OF NORMAL ANIMALS 
.WITH TOLBU';I'J\MJDE 
Animai ·No. .. · .Animal Weight Liver weight Treatment 
· · (in grams) (in. ·grams) (ml ·saline) 
1 . 320 a .. 1 .32 
2· 341 9.6 • 34 
3 298 7.8 .29 
4 356 10.1 .35 
Deca12itated 6 hours after treatment Tolbutamide 
5 400 11.4 .41 
6 361 10.7 .37 
7 334 9.1 .34 
8 341 9.4 .35 
Deca12itated 12 hours after treatment Tolbutamide 
9 256 7.1 .26 
10 319 8.9 .32 
11 ·391 10.4 .39 
12 342 9.7 .35 
Deca12itated 24 hours after treatment Tolbutamide 
13 249 8.2 .25 
14 301 9.9 .31 
-
15 278 7.3 .28 
16 367 9.1 .37 
r 
i· 
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Decapitated after 12 hours after treatment Insulin 
17 ·410 l~.l 1.0. 
,. 
. 18 309 .. 10.9 1.0 
19 311 9.4 1.0 
20 332 9.8 1.0 
• 
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TABLE XXXVI 
THE PREPARATION AND TREATMENT OF DIABETIC ANIMALS 
Animal No. 
1 
2 
3 
4 
.WITH TOLBUTAMIDE 
Animal Weight 
(in grams) 
280 
~300 
314 
322 
Liver-Weight 
(in: . grams ) 
8.1 
9.1 
10.0 
9.8 
Diabetic animals treated with s·alin:e 
5 
6 
7 
8 
289 
310 
329 
295 
8.9 
9.2 
9.4 
8.6 
Diabetic animals treated with tolbutamide 
decapitated 6 hours after treatment 
9 
10 
11 
12 
259 
265 
278 
342 
Decapitated 12 hours after treatment 
13 
14 
15 
16 
339 
351 
295 
289 
8.1 
7.6 
7.9 
9.5 
9.4 
8.9 
8.4 
7.9 
Treatment 
(ml saline) 
.28 
.30 
.31 
.32 
· ·Saline 
.28 
.31 
.32 
.29 
Tolbutamide 
.26 
.27 
.28 
.35 
Tolbutamide 
.34 
.36 
.30 
.29 
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Decapitated 24 hours after treatment Tolbutarnide 
17 360 9.9 .37 
18 345. 8.9 .35 
.. 
19 325 7.5 .33 . 
20 290 8.2 .30 
Decapitated 12 hours after treatment Insulin 
21 321 8.6 1.0 
22 317 9.2 1.0 
23 337 9.7 1.0 
24 357 10.4 1.0 
BIBLIOGRAPHY 
,. 
1. Abraham, s., Matthes, K.J., and Chaikoff, I.L.,_ "Fat~y_ Acid 
Syn.thesis from Acetate by Normal and Diabetic Rat 
Liver Homogenate Fractions,"· Journal of· Biological 
Chemistry 235, 2551 - 2560 (1960). 
2. Anderson, R.L., and Kamel, M.Y., "Glucokinase," Methods in 
Enzymology IX, 388 - 392 (1966). 
3. Ateheley, D.W., Loeb, R.F., Richards, D.N., Benedict, E.M., 
and Driscoll, M.E., "On Diabetic Acidosis, A Detailed 
Study of Electrolytic Balance Following the Withdrawal 
and Reestablishment of Insulin Therapy," Journal of 
Clinical Investigations 12, 297 - 326 (1933). -
4. Augusti, K.T., and Kurup, P.A., "Mode of Action of Oral 
Hypoglycemic Agents," Indian Journal of Biochemistry 
!1 32 - 34 (1967). 
5. Ballard, F.J., and Oliver, I.T., "Ketohexokinase, Isoenzyme 
Glucokinase and Glycogen Synthesis from Hexose in 
Neonatal Rat Liver," Biochemical Journal 90, 261 - 268 
(1964). -
6. Borondy, P.E., and Weller, S.M., "The Effect of Chlorothia-
zide on Rat Liver Glucokinase, Hexokinase, and 
Dihydroxyacetone-kinase," Proceedings of the Society 
for Experimental Biology and Medicine 118, 938 - 940 
(1965). 
7. Boyer, P.O., "Spectrophotometric Study of the Reaction of 
Protein Sulfhydryl Groups with Organic Mercurials," 
-Journal of the American Chemical Society, 4331,... 4337 
(1954). - -
8. Butterfield, W.J., Fry, I.K., and Whichelow, M.J., "Hypo-
glycemic Action of Phenformin, Studies in Diabetes 
After Short Term Therapy," Lancet±._, 563 - 567 (1961). 
9. Chaikoff, I.L., "Metabolic Blockers in Carbohydrate Metabo-
lism i-n Diabetes," Harvey Lectures Q, 1951 - 1952 
(1953). 
93 
94 
10. Clark, G.A., "The Influence of the Vagus on the Islets of 
.Langerhans," Journal of Physiology 59, 466 - 471 
(1925). . 
11. Clark, G.A., "Interrelation of Parathyroid Suprarenals and 
Pancreas," Journal of Physiology 58, 294 - 301 (1923.). 
12. ciark., G~A;, "Action of Guanidine Salts on Dilute Glucose 
Solutions," Journal of Physiology 57 1 .LVIII - LX 
13. Clark, D.W., "Effect of Administration of Chloropro:pamide 
Upon the Carbohydrate Metabolism of Isolated Tissue," 
Annals of the New York Academy of Science 74, 478 -
481 (1959)-. - -- - - -
14. Colowick, S.P., and Kalckar, H.M., "An Activator of the 
Hexokinase System," Journal of Biological Chemistry 
137, 789 - 790 (1943). 
15. Crane, R.T., and Sols, A., "Animal Tissue Hexokinases," 
Methods in Enzymology f, 277 - 287 (1955). 
16. Dechatelet, L.R., and McDonald, H.J., "The In Vitro Effect 
of Two Oral Hypoglycemic Agents on Hepatic Protein 
Synthesis," Proceedings of the Society of Experimental 
Biology and Medicine 122, 765 - 768 (1966). 
17. Dechatelet, L.R., and McDonald, H.J., "Effect of In Vivo of 
Various Oral Hypoglycemic Agents on Hepatic-Protein 
·Synthesis," Proceedings of the Society of Experimental 
Biology and Medicine 127, 415 - 418 (1968). 
18. DiPietro, D .L., and Weinhouse ,. S., "Hepatic Glucokinase in 
the Fed, Fasted and Alloxan-Diabetic Rat," Journal of 
Biological Chemistry 235, 2542 - 2545 (1960). 
19. Franke, H., and Fuchs, J., "Eines Neues Antidiabetisches 
Prinzip Ergebnisse Klinischer Untersuchungen," 
Deutsche Medizinsche Wochenschrift 80, 1449 - 1452 
20. Frawley, T.F., "Further Studies on the Significant Role of 
Liver in Sulfonylurea Hypoglycemia," Annals of the 
New York Academy of Science 82, 460 - 476 (1957_) __ _ 
21. Frawley, T.F., Shelly, T.F., Runycen, J.W., Margulies, E.J., 
and Cihcotti, I.J., "Studies on the Significant Role o 
95 
Liver in Sulfonylurea Hypoglycemia," Annals of the 
~.York Academy of Science 82, 460 - 476 (1959-)-.-
_22. Fritz, l.B., .Weinstein,. M.,. Morton, J.U., and Levine, R., 
"The Effect of Carbutamide on Blood Sugar Levels of 
Depancreatized Dogs Given Insulin,"·Endocrinology_IX, 
76 - 79 (1956) • 
23. Fritz, I.B., Morton, J.U., Weinstein, M., and Levine, R.A., 
·"Studies of the Mechanism of Action of Sulfonylurea," 
Metabolism~, 744 - 748 (1956). 
24. Frohman, C.E., Orten, J.M., and Smith, A.H., "Levels of Acid 
in the Citric Acid Cycle," Journal of Biological 
Chemistry 193, 803 - 812 (1951). 
25. Gazith, I., Schulze, I.T., Gooding, R. H., Womack, F.R.C., 
and Colowick, S.P., "Multiple Forms and Subunits of 
Yeast Hexokinase," Annals of the New York Academy of 
Science 151, 307 - 330 (1968). 
26. Gibson, D.M., and Hubbard, D.D., "The Acetyl CoA-Malonyl CoA 
Condensation Reaction in Rat Liver During Starvation 
and Fat-Free Refeeding," Biochemical Biophysical 
Research Communication~, 339 - 343 (1961). 
27. Grodsky, G.M., Karam, J.H., and Forsham, P.H., Metabolism 
12, 278 - 279 (1963). 
28. Harper, H.A., "Metabolism of Carbohydrates, Cholesterol, 
Lipids, and Proteins," Review of Physiological 
Chemistry, Lange Series, 215 - 288 (1967). 
29. Harper, P.V~, Neal, W.B., and Hlavacek, G.R.,· "Acetate 
Utilization in the Dog," Metabolism ±.1 62 - 80 (1953). 
30. Harris, J.I., and Li, L.H., "The Biological Activity of 
Enzymatic Digestion of Insulin," Journal of the 
American Chemical Society 74, 2945 - 2946 (1952). 
31. Hennes, A.R., Woschenberger, B.L., and Fajan, S.S., 
"Comparative Effect of Insulin and Orinase on Blood 
Levels of Pyruvate and Alpha-Ketoglutarate·in Normal 
Subjects," Metabolism~, 63 - 69 (1957). 
32. Ilyin, V.S., "Hormonal Regulation of Liver Hexokinase 
96 
Activity," Advances in Enzyme Regulation ~, 151 - 175, 
(1963). . 
33. Jacobs, G. ,. Reichard, G.A., Goodman, E.H., Freedman, B., 
and Weinhouse, s .. , "Action of Insulin and Tolbutamide 
on Blood Glucose Entry and Removal," Di~betes 7, 
358 ~ 364 (1958). 
34. Joshi, D.M., and Jagannathan, v., "Hexokinase, Brain," 
Methods iri EnZYi;nOlogy IX; 371 - 375 (1967). 
35. Joslin, E.R., Root, H.F., White, P., and Bailey, c.c., 
"Treatment of Diabetes Mellitus," 8th Edition, Leo and 
Febriger, Philadelphia, Pa. (1946}. 
36. Katzen, H.M., "Multiple Forms of Hexokinase in Rat: Starch 
Gel Electrophoretic Evidence for an Effect of Diabetes 
and Insulin In Vitro," Diabetes g, 518 - 519 (1966). 
37. Katzen, H.M., "The Multiple Forms of Mammalian Hexokinase 
and Their Significance to the Action of Insulin," 
Advances in EnzYi;ne Regulation 5, 335 - 354 (1967). 
38. Katzen, H.M., and Schimke, R.T., "Multiple Forms of Hexo-
kinase in the Rat: Tissue Distribution, Age Depending 
and Properties," Proceedings of the National Academy 
of Science 54, 1218 - 1225 (1965). 
39. Kenkare, u., Schulze, I.T., Gazith, J., and Colowick, S.P., 
"Subunits and Multiple Forms of Yeast Hexokinase," 
Abstracts of the Sixth International Congress of 
Biochemistry, New York, N. Y., VI 510, 477 - 478 
(1964) • 
40. Katzen, H.M., "The Effect of Diabetes and Insulin In Vivo 
and In Vitro on a Low Form of Hexokinase froiilvarious 
Rat Trssue," Biochemical and Biophysical Research 
Communication 24, 531 - 536 (1966). 
41. Keston, and Teller, "Blood Glucose," Technical Bulletin 
No. 6073D, Beckman, Ultramicro-analytic System 
Instruction Manual. 
42. Krahl, M.E., "Hormones and the.Metabolism of Isolated Tissue 
of Rats," Diabetes~, 26 - 30 (1953). 
43. Krahl, M.E.~ and Pehos, J.C., "A Direct Effect of Insulin on 
Liver," Federation Proceedings 20, 193 (1961). 
44. 
45. 
46. 
47. 
48. 
49. 
so. 
51. 
52. 
53. 
54. 
97 
Krahl, M.E., "Incorporation of C-14 Amino Acids into Pep-
ti(:ies by Normal and Diabetic Rat Tissue," Science 116, 
524 (1952). 
Kuntz, M., and McDonald, M.R., "Crystalline Hexokinase," The 
. Journal of General Physiology 29, 393 - 412 (1946) .--
Langerhans, P., "Contributions to the Microscopic Anatomy of 
Pancr~as," Berlin, G., Lange 1869 Reprint of the origi 
nal-German with an English translation and an Intro-
ductory Assay by H. Morrison, The John Hopkins Press, 
Baltimore, Md., (1937). · 
Levine, R., Goldstein, M., Klein, s., and Huddlestun, B., 
"Action of Insulin on Distribution of Galactose in 
Eviscerated Nephrectomized Dogs," Journal of Biologi-
cal Chemistry 179, 985 - 998 (1949). 
Levine, R., and Goldstein, M.S., "On the Mechanism of Action 
of Insulin," Recent Progress in Hormone Research 11, 
343 - 373 (1955). 
Levine, R.A., and Lewis, I.E., "Glycolytic Effect of 
Dibutyryl Cyclic Adenosine-3-5-Monophosphate in 
Perfused Rat Liver," Biochemical Pharmacology 18, 
15 - 20 (1969). 
Levine, R., "Analysis of the Action of the Hormonal Antago-
nists of Insulin," Diabetes 13, 362 - 365 (1964). 
Levitram, R., and Havin, E., "Hexokinase Activity in Intesti 
nal Mucosa of Hypophysectomized Rats," American 
Journal of Physiology 215, 330 - 333 (1968). 
Liebraw, R., and He-lerstein, H.K., "Cardiac Complications 
of Diabetes Mellitus," American Journal of Medicine 
l1 660 - 670 (1949). 
Little, J.F., and Best, C.H., "The Occurance of Hypoglycemia 
Producing Substance in Bacteria," Journal of Biologi-
cal Chemistry 59, XXXVIII - XXXVIII (1924). 
. . 
Loubatieres, A., "Estrude Physioloigue Et Pharmalodynamique 
- de Certains ·Berives· Sulfamides Hypogycemiants," 
Archives Internationales De Physiologie 54, 174 - 177 
(1946). 
98 
55. McLamore, W.M., Fanelli, G.M., Pan, J.Y., and Lawback, G.P., 
".Hypoglycemic Sulfonylureas; Effect of Structure on 
Activity.," Annals of the ~ York Academy of Science 
'14' 443 - 448 (1959). . .. . . 
56. Mering, Von, Minkowski,. and Slate;+, J.D.H., "Oral Hypo~ 
glycemic Compounds," Progress in Medicinal Chemistry I 
Butler Worths, London· (1961). 
57. Meyerhof·,. o.,. "Hexokinase," Biochemische · Zeitschrift 183, 
176 - 180 (1927). 
58. Miller, H., "Physiologische und Chemische Studium uber die 
Tanzetsche Guanidin Base Galpine," Zeitschrift 
Biologie ~, 239 - 264 (1927). 
59. Niemeyer, H.L., Clark-Turri, and Rabajille, E., "Induction 
of Glucokinase by Glucose in Rat Liver," Nature 198, 
1096 - 1097 (1963). -
60. Ross, E.J., "The Influence of the Permeability of the Blood 
Aqueous Barrier to Glucose," Journal of Physiology 116 
414 - 422 (1952). 
61. Salas, M., Venuela, E., and Sols, A., "Glucokinase Synthesis 
Insulin Dependent in Rat Liver," Journal of Biological 
Chemistry 238, 3535 - 3537 (1963). 
62. Sanger, F., "The Terminal Peptide of Insulin," Biochemical 
Journal 45, 563 - 574 (1964). 
63. Sanger, F., Thompson, E.O.P., and Kitai, R., "The Amide 
Group of Insulin," Biochemical Journal 45, 563 - 574 
(1964). . 
64. Sanger, F., Smith, L.F., and Kitai, R., "The Disulfide 
Bridge of Insulin," Biochemical Journal 58, VI - VII 
(1954). 
65. Sanger, F., Smith, L.F., and Kitai, R., "The Amide Group of 
In§;ulin," Biochemical Journal, 59, 509 - 518 (1955). 
66. Schimke, R.T., and Grossbard, L., "Studies of Isozymes of 
Hexokinases in Animal Tissues," Annals of the New York 
Academy of Science 151, 332 - 348 (1968):" ~- -~ ~~ 
99 
/' 
67. Schonhe.imer, D., "Tei1 uber die Quantitaven Verhalturise des 
Cholesterins und der Cholesteri.nester," Physiological 
Chernische 160, 61 .,.. 76 (1926). . - . . ... 
-- . 
68. Schulze, I.T., Gazith, J., and Gooding, R.H., "Hexokinase: 
Baker's Yeast_,·~ Methods in Enzymology IX,. -~76 - 380 
(1967). 
69. Schulze, I.T., Gazith, J., and Gooding, R.H., "Hexokinase," 
· Methods in Enzymology I-x, 376 - 381 (1966) .. · 
70. Sharma, c., Manjeshwar, R., and Weinhouse, s., "Hormonal and 
Dietary Regulation of Hepatic Glucokinase," Advances 
in Enzyme Regulation 2, 189 - 200 (1967). 
71. Sinex, F.M., MacMullen, J., and Hastings, A.B., "The Effect 
of Insulin on Incorporation of C-14 into the Protein 
of the Rat," Journal of Biological Chemistry 198, 
615 - 619 (1952). 
72. Slein, M.W., Cori, G.T., and Cori, C.F., "A Comparison Study 
of Hexokinase.from Yeast and Animal Tissue," Journal 
of Biological Chemistry 186, 763 - 780 (1950). 
73. Slein, M.W., Cori, G.T., and Cori, C.F., "A Comparative 
Study of Hexokinase from Yeast and Animal Tissue," 
Journal of Biological Chemistry 186, 736 - 780 (1950). 
74. Smith, E.L., Hill, E.L. and Bunan, A., "Activity of Insulin 
Degraded by Leucine and Amino Peptidase," Biochemica 
Eta Biophysica ACTA 29, 207 - 208 (1960). 
75. The Papyrus Ebers, The Greatest Egyptian Medical Documents 
Translated by B. Eddell, Copenhagen, 1937, Quoted by 
Williams, R.H., Editor~ Diabetes, Harper and Brothers, 
New York, N. Y. (1962). 
76. Pomeranze, J., Herley, F., Mouratoff, M.T., "Clinical Report 
of a New Oral Hypoglycemic Agent," Proceedings of the 
Society of Experimental Biology and Medicine 95, 
193 - 194 (1957). . . . 
7 7 • · Unger, G. , Freedman, L. , and Sha par io, · S . L. , "Pharmacolo-
gical Studies on a New Oral Hypoglycemic Drug (23163), 
Proceedings of_ the. Society of Experimental Biology and 
Medicine 95, 190 - 194 (1957). 
78. 
79. 
. 100 
Vinuela, E., Salas, M., and Sols, A., "Glucokinase and 
Hexokinase in Liver in Relation to Glycogen Synthesis,' 
Journal of Biophysical Chemistry 238, 1175 - 1177 · 
. (1963) •. ' -
Von Euler, H. and A.dler, E.Z., Physiological Chemistry 235, 
122 (1935). 
80. Von Holt, C. , Von Ho.l t, L. , Kroner, B. , and Kuhnaw, J. , 
"Chemische Ausschaltung der A-Zellen de:r Langer-
hanschen Insulin," Archives .Fur Experimentelle 
Pathologie, 224, 66 - 77 (1955). 
81. Walker, D.G., and Parry, M.J., "Glucokinase," Methods in 
Enzymology ~, 381 - 388 (1966) 
82. Walker, D.G., "The Nature and Function of Hexokinase in 
Animal Tissue", Essays in Biochemistry~, 33 - 67 
(1966). 
83. Warren, s., "The Pathology of Diabetes Mellitus," 2nd 
Edition, Leo and Febiger, Philadelphia, Pa. (1938). 
84. Watambe, C.K.,. "The Change of Phosphate and Calcium Content 
in Serum in Guanidine Tetany and the Relation Between 
the Calcium Content and Sugar in the Blood," Journal 
of Biological Chemistry 36, 531 - 546 (1918). 
85. Watambe, C.K., "Studies in the Metabolic Changes Induced by 
Administration of Guanidine Bases," Journal of 
Biological Chemistry 33, 253 - 265 (1918). ~ 
86. Williams, R.H., Tanner, D.C., and Odell, W.D., "Hypoglycemic 
Action of Phenethyl-Amyl and Isoamyl-Diguanide," 
Diabetes J_, 87 - 92 (1958). 
87..- Williams, R.H., Editor, Diabetes, Harper and Brothers, 
New York (1962) • · 
88. Willis, T., "Opera Omnia Genevae," 1676 - 1680, Quoted in 
Williams, R.H .. , Edi tor, Diabetes, Harper and Brothers, 
New York (1962). 
89. Winegrad, A.I., and Renold,·A.E., "Studies on Rat Adipose 
Tissue· In Vitro: II The Effect of Insulin on Metabo-
lism o-fSpecifically Labeled Glucose, •r Journal of 
Biological Chemistry 233, 273 - 276 (1958). 
101 
90. Winegrad, A.I., and Renold, A.E., "Studies on Rat Adipose 
Tissue.In Vitro:. I The Effect of insulin on~lucose, 
Pyruvate, and Acetate," Journal of Biological 
Chemistrx ~_, 26'7 -. 272 (1958). . . . . 
91. Winqaus, A., "Uber d~.n ~ehalt Norm..,.les und Alheromat9r. 
Aorten an Cholestrin .und Cholestrinestern," 
Zeitschrift Physiological Chemische 67, 174 - 176 
(1910) • 
92. Wittenhangen, G., and Mohnike; G., "Uber die Orale 
Behandlung des Diabetes Mellitus Mit N-(4-Methyl-
Benzol Sulfonyl)-N-Butyl-Honstoff (D860) ," Deutsche 
Medizinsche Wochenschrift 81, 887 - 888 (1956). 
93. Wittenhangen, G., Mohnike, G., and Langenbeck, w.z., 
Physiological Chemistry 316, 157 (1959). 
94. Oawke, H., and Bawk, I., "Metabolism of Phenethylbiguanide," 
Metabolism 12, 319 - 320 (1963). 
95. Upjohn Company, "Diabetes Mellitus and the Normal Metabolic 
Pathways," "The Diabetic State and the Action of 
Insulin," ~ Monograeh £!!.Diabetes Mellitus, 6 - 51 
(1969). 
96. Banting, F.G., and Best, C.H., "Pancreatic Tissue," Journal 
of Laboratory and Clinical Medicine 7, 462 - 472 
. Tr922). - -
97. Pilkis, S.J., and Krahl, M.E., "Apparent Molecular Weights 
of Rat Liver Glucokinase and Hexokinase," Federation 
Proceedings 25, 523 (1966). 
98. Campbell, G.D., "The Oral Hypoglycemic Agents," Medicinal 
Chemistry Series~, 1 - 283 (1969). 
99. Umber, F., Deutsche Medizinische Wochenschrift 52, 1121 
(1927) • 
APPROVAL 
The thesis submitted by Geoffrey A. Karasek has been 
. . -· 
read and approved by three members of the faculty of Loyola 
University. 
The final copies have been examined by the director of 
the thesis and the signature which appears below verifies the 
fact that any necessary changes have been incorporated, and that 
the thesis is now given final approval with reference to content, 
form, and mechanical accuracy. 
The thesis is therefore accepted in partial fulfillment 
of the requirements for the Degree of Master of Science. 
.Date Signature of Adviser 
